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SPROUTY 2: A NOVEL ATTENUATOR OF B CELL RECEPTOR 
AND MAPK SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA 
Ashima Shukla, Ph.D. 
University of Nebraska Medical Center, 2016 
Supervisor: Shantaram S. Joshi, Ph.D. 
Clinical heterogeneity is a major barrier to effective treatment of Chronic Lymphocytic 
Leukemia (CLL). Emerging evidence suggests that constitutive activation of various 
signaling pathways plays a role in the heterogeneous clinical outcome of CLL patients. 
MAPK-Erk signaling represents one such pathway with a demonstrated role in CLL 
pathogenesis. In this study, we have investigated the role of Sprouty2 (SPRY2) as a 
negative regulator of receptor and non-receptor tyrosine kinase signaling in the 
pathogenesis of CLL. We show that SPRY2 expression is significantly decreased in CLL 
cells, particularly from poor prognosis patients compared to those from good prognosis 
patients. Over-expression of SPRY2 in CLL cells from poor prognosis patients 
decreased their proliferation while increasing their apoptosis. Conversely, down-
regulation of SPRY2 in CLL cells from good prognosis patients resulted in increased 
proliferation. Furthermore, CLL cells with low SPRY2 expression grew more rapidly in a 
xenograft model of CLL. Strikingly, B-cell specific transgenic over-expression of spry2 in 
mice led to a decrease in the frequency of B1 cells, the precursors of CLL cells in 
rodents. Mechanistically, we show that SPRY2 attenuates the BCR and MAPK-Erk 
signaling by binding to and antagonizing the activities of RAF1, BRAF and SYK in 
normal B cells and CLL cells. We identified that SPRY2 is targeted by miR-21 which in 
turn leads to increased activity of Syk and Erk in CLL cells. We also show that the 
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activation of miR-21 is mediated by IL-10 induced STAT3 signaling in CLL cells. Taken 
together, these results establish SPRY2 as a critical negative regulator of BCR-mediated 
MAPK-Erk signaling in CLL, thereby providing one of the molecular mechanisms to 
explain the clinical heterogeneity of CLL.  
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Chapter I 
Introduction 
“An Overview on Chronic Lymphocytic Leukemia” 
Chronic Lymphocytic Leukemia (CLL) is the most prevalent form of adult 
leukemia, accounting for about 35% of adult leukemias diagnosed in the United States 
(1-3). There are around 15,000 newly diagnosed individual with CLL and approximately 
4,500 deaths are caused by CLL each year (1). CLL is a clinically heterogeneous B-cell 
clonal lymphoproliferative disorder characterized by >5 × 109/L peripheral B-lymphocytes 
coexpressing CD5, CD19, and CD23 and a weak expression of CD20, CD79b, and 
surface immunoglobulin (sIg). The incidence of CLL significantly increases with age. 
With a median age lying in between 67 to 72 years CLL affects more male patients than 
female patients with a ratio of 2:1 (3,4).   
Clinical heterogeneity makes CLL a challenging disease to provide effective 
treatment to patients. Along with the therapy of CLL, patients often requires an active 
management of a wide range of internal medicine problems related to chronic immune 
deficiency, infections, autoimmune complications and prevention of secondary cancers. 
The complexity of these related problems are mainly due to the clinical prognosis of CLL 
patients.  
Clinical Heterogeneity and Prognosis in CLL:  
CLL is clinically heterogeneous, with varying clinical outcomes and possibly 
distinct molecular pathogenesis (5). The overall median survival for patients with CLL is 
about 10 years however, the duration of survival differs substantially among individual 
patients. About one-third of CLL patients never need treatment. In another third, the 
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disease has an initial indolent phase, which subsequently leads to progression, whereas 
the remaining third manifest aggressive disease from the onset (3,4). Based on the 
Immunoglobulin variable heavy chain (IgVH) mutational status, chromosomal 
abnormalities and cell surface markers, CLL patients are categorized into subgroups 
with good or poor prognosis. Poor prognosis patients were defined by un-mutated 
immunoglobulin heavy chain variable (IgVH)-segments, high Zap70, 11q22 deletion, 17p 
deletion, trisomy 12 and/or high CD38 expression. Good prognosis patients were 
defined as having mutated IgVH, low Zap70, 13q14 deletions and/or low CD38 
expression as shown in Figure 1.  
Specific genomic alterations like deletion on the long arm of chromosome 13 (Del 
13q14) leads to leukemic transformation (6). These abnormalities are caused by deletion 
of specific micro-RNA (miR) genes like miR-15a and miR16a which leads to impaired 
apoptosis in CLL cells (7). This aberration is found in around 55% of all CLL patients 
(1,7). Further, aberrations like deletion of the long arm of chromosome 11 (Del 11q), 
which is linked to deletion of ataxia-telangiectasia mutated (ATM) gene has much more 
aggressive disease onset (8). This aberration occurs in around 6% to 18% of CLL 
patients making it the second most common chromosomal aberration in CLL.  Deletion 
of the short arm of chromosome 17 (Del 17p) which is associated with loss of p53 is 
found in about 7% of CLL patients and Trisomy 12 found in 12% to 16% patients whose 
role in pathophysiology of CLL is still unknown, seem to occur later in the course of the 
disease and predict a worse outcome (1,2).  
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Figure 1 Prognostic markers in chronic lymphocytic leukemia: 
 
Schematic diagram showing the prognostic markers for classifying CLL patients 
into good and poor prognosis groups.  
 
 
 
 
 
 
4 
 
In general CLL can be categorized into two major groups: mutated and 
unmutated CLL (9). CLL derived from antigen inexperienced immature B cells 
(unmutated IgVH) determined by IgVH mutational status are predicted to have poorer 
clinical outcome when compared with antigen experienced post germinal center mature 
B cells (mutated IgVH). The molecular mechanism of unmutated IgVH leading to poor 
prognosis of CLL patients still remains ambiguous. However, gene expression profiling 
has shown that unmutated IgVh CLL and mutated IgVh CLL have distinct gene 
expression signature. The expression of Zeta-associated protein 70 (Zap70) is much 
higher in CLL cells isolated from unmutated IgVH CLL patients when compared with 
those from mutated IgVH CLL patients (10). Several reports have demonstrated that the 
high expression of Zap 70 can be used as a surrogate marker for unmutated IgVH CLL 
patients. It has been also demonstrated that the CLL cells expressing high levels of 
Zap70 also retains increased B cell receptor signaling.  
Another molecule which is used as a prognostic indicator in CLL is CD38 
molecule (11). CD38 is a single chain type II transmembrane glycoprotein which is 
present on variety of hematopoietic cells. The cellular function of CD38 includes a 
complex entoenzymatic activity, facilitating cell adhesion, signal transduction and 
calcium signaling (11). The expression of CD38 in normal B cells exhibit a discontinuous 
pattern during the process of B cell development. The CD38 molecule is detected in 
levels in B cells precursors, germinal center and plasma cells while circulating peripheral 
B cells and tonsillar B cells have markedly lower CD38 surface expression. The role of 
CD38 in CLL pathophysiology is presently unknown. However, it is tempting to speculate 
that differences in CD38 ligands interaction between CLL clones may influence their 
proliferative behavior (11).   
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Current Therapy used for CLL patients:  
 CLL is slow growing B cell neoplasm with highly variable clinical course. For 
more than a decade standard therapeutic approach for CLL patients has been “wait and 
watch”. For past few years CLL has undergone an exciting therapeutic transformation. 
Prior to this, patients with relapsed disease had generally unfavorable clinical outcome. 
Chemotherapy or single agent immunotherapy were the standard therapies. Stem cell 
transplantation is the only known curative therapy, which recuses about 50% of relapsed 
patients. However, transplanted related morbidity and mortality in older population still 
remain major concern. The introduction of two oral kinase inhibitor (Ibrutinib and 
Idelalisib) has significantly changed the standard care for relapsed patients (3).  
 Idelalisib is an oral reversible p110δ isoform specific phosphoinositide-3 kinase 
(PI3K) inhibitor. As δ isoform is specific to B lymphocytes therefore, this drug specifically 
targets CLL cells. It is currently approved along with rituximab for the treating relapsed 
and refractory CLL patients. Combination of idelalisib with rituximab led to overall 
response rate to 77% whereas rituximab alone was around 15%. On the other hand 
Ibrutinib is an oral, selective and reversible Brutons tyrosine kinase (BTK) inhibitor. 
Ibrutinib has been shown to inhibit the BCR signaling, prevention of CLL cells homing 
both in vitro and in patients. Currently, Ibrutinib is approved for relapsed or refractory 
CLL and CLL patients with Del 17p with an overall response rate of 91%. Along with 
these drug Venetoclax, BCL2 inhibitor is also a selective inhibitor however, it is not FDA 
approved yet (3,4). Interestingly, in phase 1 study in combination with rituximab, the 
overall response rate was around 88%, at a median follow-up of 7 months (3).  
 As the target therapies has become more established in CLL, our understanding 
towards the molecular mechanism has also been evolved. Recent reports also indicate 
6 
 
emergence of resistance in a portion of CLL patients treated with targeted therapies. 
However, the mechanism through which CLL patients develop resistance to these drugs 
still remains ambiguous.  Ibrutinib is the only targeted agent in CLL whose resistance 
mechanism is understood in certain percent of ibrutinib relapsed patients. Whole exome 
sequencing revealed the acquired mutations in BTK at the binding site of ibrutinib and in 
phospholipase Cy2 (PLCy2) following Ibrutinib therapy. The mutations in PLCy2 is gain 
of function mutation thus activates MAPK and Pi3K signaling in relapsed patients.  
 Although with the inclusion of oral selective drugs have improved the 
management of refractory and relapsed disease, still the major challenge is to manage 
the resistant disease. Consequently, CLL still remains incurable, however, these oral 
inhibitors have significantly improved the life span of CLL patients.  
Mutations and associated signaling pathways involved in CLL pathogenesis:  
Recent studies with whole genome sequencing and genome wide association 
study analysis has uncovered recurrent somatic gene mutations that occur in CLL cells 
in parallel to the above-mentioned structural genomic aberrations. Of these, mutations 
affecting the genes such as NOTCH1, MYD88, TP53, ATM, and SF3B1 seem to be 
more common and to have prognostic impact. However, these somatic mutations play 
central role in driving tumorigenesis, over course of therapy by deregulating several 
signaling pathways (12).  
About 11% of those mutation are present in the pest domain of NOTCH1 which 
might be one the mechanism of prolonged activation of Notch signaling. Inactivating 
mutations found in TP53 and ATM genes, lead to reduction in DNA damage. Mutations 
in critical adaptor protein Myd88 leads constitutive activation of NFkβ signaling.  
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One such study with 58 CLL patient’s samples demonstrated 40% of mutation 
leads to activation of NOTCH signaling making it the most common deregulated 
signaling pathway (13). Furthermore, same study also demonstrated that 36% of CLL 
patients possess mutations associated with activation of MAPK signaling pathways (13). 
However, few other studies have shown mutations leading to activation MAPK signaling 
pathway are central to CLL driver events (12, 14). Recent studies have identified BRAF 
mutations in small cohort of CLL patients, however BRAF inhibitor has very little or no 
effect on CLL cells in vitro (13, 14). Highlighting some other mechanism leading to 
activation of MAPK signaling in CLL cells. 
Although, historically CLL was considered as a malignancy of long lived matured 
B-cells, recently it was shown that there is a small actively proliferating population which 
resides in micro-anatomical sites known as proliferation centers in BM and LNs (15). 
CLL cells receive proliferation and survival signals in proliferation centers (16-18). These 
stimuli are primarily facilitated by B-cell receptors, chemokine receptors like CXCR4 
receptor, BAFF receptors, CD40 and other CLL cell surface receptors (17). Once the 
ligand binds to its receptor they activate downstream signaling pathways including NF-
kB, MAPK-Erk and Akt signaling known to promote survival and proliferation of CLL cells 
(18). In line with these findings, our recent studies on tumor microenvironment have 
demonstrated that constitutive activation of BAFF-APRIL, NF-kB, MAPK-Erk and BCR 
pathways are indeed important for proliferation and survival of CLL cells (18).  
Our studies along with several other reports revealed a critical role for B-cell 
receptor (BCR) and MAPK-Erk signaling in the survival and proliferation of CLL cells (18-
21). Similarly, BCR signaling is upregulated in CLL, providing a chronic stimulus for their 
proliferation (18-21). The role of BCR and MAPK signaling in CLL cells pathogenesis is 
now well-accepted. 
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A role for SPROUTY proteins in regulating CLL pathogenesis 
Hyperactivation of MAPK-Erk and BCR signaling is hallmark of B cell 
malignancies including CLL (12-14). These pathways can be hyperactivated by above 
described genetic aberrations or by loss of function mutations or through deregulation of 
negative regulators like NF1, SPRED, or SPROUTY (SPRY) proteins (22-25). Therefore, 
to identify these deregulated genes which might be playing role in the pathogenesis of 
CLL we perform transcriptome analysis. We observed that the expression of SPRY2 was 
significantly downregulated in CLL cells isolated from poor prognosis patients when 
compared with those from good prognosis patients.  
 SPRY was first identified as a general inhibitor of RTK mediated signaling in 
Drosophila in a genetic screen for regulators of eye and tracheal development. SPRY2 is 
1 of the 4 mammalian homologs of Drosophila sprouty gene, which encodes for 32- to 
34 kDa protein (25, 24, 23). The vertebrate SPRY proteins are homologous to 
Drosophila protein at the cysteine rich C terminus whereas the N terminus differs 
dramatically. SPRY proteins specifically inhibits ligand induced RTK mediated signaling 
therefore might have a critical role in BCR signaling (25-30). Thus, typically these 
proteins negatively regulates the cellular proliferation, survival and migration. 
Alternatively, sprouty can increase cell proliferation by enhancing MAPK-ERK signaling 
in naive T cells after T-cell receptor (TCR) engagement or after EGF receptor (EGFR) 
activation in multiple nonlymphoid cell types (28,31).  
 Precise mechanism through which sprouty proteins modulate RTK signaling is 
still ambiguous, and several mechanisms for pathway inhibition or activation have been 
proposed, including antagonism of MAPK-ERK pathway signaling at the level of RAS 
activation, RAF activation, or upstream of RAS by sequestering the adaptor, GRB2 (26). 
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The interaction between SPRY2 and CBL sequesters CBL ability to ubiquinates of 
EGFR, leading to augmentation of epidermal growth factor (EGF)-dependent MAPK-
ERK signaling pathway (27, 28).  
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Figure 2 Known interacting partners for SPROUTY2: 
  
 
Schematic diagram generated using String database. The figure shows the 
known interacting partners for SPRY2 in several cellular systems.  
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Figure 3 Structural features of SPRY2 and its known interacting partners.  
 
The orange box shows the SH2-domain binding motif (amino acids 50-60) that binds to 
CBL, PP2A and GRB2; the key tyrosine residue Y55 is also indicated. The conserved 
cysteine-rich SPRY domain (amino acids 178-293) is crucial for its ability to interact with 
signaling molecules such as FRS2 and SHP2. The SPRY domain is also responsible for 
membrane translocation (MTD). There is an SH3-domain binding motif (amino acids 
303-309) shown in blue at the C-terminal end of SPRY2 that also binds to GRB2. 
Proteins that interact with SPRY physically or functionally. Known functional 
consequences of the interactions are indicated in the boxed areas. 
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As critical attenuator of RTK signaling, SPRY proteins plays an important role in 
attenuating ligand induced pro-growth signaling responses which can inhibit malignant 
transformation (32-36). Sprouty genes including Spry2 have been reported to be 
epigenetically repressed or targeted by miRNA-21 in several cancers of the prostate, 
lung, liver, lymphoma and breast (37-47). Where they function mainly as tumor 
suppressors by antagonizing the MAPK-ERK pathway (45-47). Consistent with this role, 
the expression of sprouty proteins is induced by negative feedback mechanism to 
reduce MAK-Erk signaling, by interacting with several proteins like RAF, BRAF, RAS, 
PTPN11, GRB2, EGFR, and SRC (48-51).  
Role of miRNAs in CLL and their target genes  
MicroRNAs (miRNAs) are small non coding RNA molecules that modify the gene 
expression post-transcriptionally (37-39). MiRNA regulates the expression of multiple 
genes by inhibiting translation and/or stability of target messenger RNA (40,41). Over 
the past decade an essential role of miRNAs has emerged in cancer prognosis and 
pathogenesis. In CLL, miRNAs are important for disease prognosis and have been 
associated with the pathogenesis of the disease. Identifying the loss of miR-15a and 
miR-16-1 located at 13q14.3 (minimal deleted region) in CLL was the first study 
demonstrating the involvement of miRNAs in human disease (42). These miRNAs target 
several cell cycle regulators and anti-apoptotic genes like CDK6, CDK4, CHK1, BCl-2, 
etc. leading to decreased survival of CLL cells (43). Loss of 13q14.3 locus harboring 
miR15a/16-1; is the most common chromosomal aberration in CLL patients. Importantly, 
deletion of a region syntenic to human 13q14 or deletion of miR15a/16-1 alone leads to 
spontaneous CLL development at low penetrance in rodents (43). Interestingly, patients 
with 13q14 deletion have comparatively better prognosis (44).  
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Recently, several studies have shown that high miR-21 expression is associated 
with poor prognosis in CLL patients (10,11). MiR-21 is located at 17q.23.1 and is highly 
expressed in CLL patients with 17p locus deletion when compared to CLL patients with 
wild type 17p locus (11). Importantly, 17p deletion leads to loss of p53 and have been 
associated with poor patient outcomes (45). High miR-21 expression in CLL patients is 
linked to refractoriness to Fludarabine and associated to shorter overall survival (46). 
Also, Crespo etal reported that high Zap70 leads to induction of miR-21 expression in 
primary CLL cells (47). Together these lines of evidence demonstrate that miR-21 is 
overexpressed in CLL patients with poorer outcome.  
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Figure 4 MiR-21 targets SPRY2 at conserved 5’UTR region: 
 
 
This was generated using miR database, showing that Mir-21 targets SPRY2 at 
an evolutionary conserved region.  
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MiR-21 is an oncomir and is overexpressed in several other malignancies 
(48,49). Spry2, Spry1, PDCD4, TPM1 and PTEN are some of the known targets of miR-
21 (12,49,50). However, it is uncertain whether Pten is a direct target of miR-21 or its 
destabilization occurs due to down regulation of Spry2 mediated by miR-21. Several 
groups have demonstrated that miR-21 directly targets and downregulates expression of 
Spry2 to activate MAPK-Erk signaling in human gliomas and many other malignancies 
(9,51). However, the role of miR-21 in the pathogenesis of CLL was not fully understood. 
Our studies have demonstrated that miR-21 targets SPRY2 to hyperactivate Syk 
mediated BCR and MAPK signaling. 
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Overall Significance:  
Our recent studies revealed active MAPK and BCR signaling as a feature of CLL 
cells (18). Additionally, identification of mutations leading to constitutive activation of 
MAPK signaling in a significant proportion of CLL patients (36%) further entitle MAPK 
signaling to be crucial for CLL (12). Also genome wide association and whole exome 
sequencing studies have demonstrated that the activation of MAPK signaling plays a 
role as central driver event during the process of CLL disease progression (13,14). 
Therefore, it is imperative to study the role of Spry2 as a regulator of B cell receptor and 
MAPK signaling in CLL to better define the molecular pathogenesis of CLL. The insights 
gained from these studies can be used to identify new therapeutic targets for specific 
therapies against CLL. Thus, this research proposal is very significant because it 
advances the field and will identify the potential therapeutic targets to effectively treat the 
currently incurable, most common adult leukemia in the western world. 
HYPOTHESIS:  
Based on our preliminary results showing decreased expression of SPRY2 in 
CLL cells isolated from poor prognosis patients and activated MAPK-Erk and BCR 
signaling in CLL cells (18). I hypothesize that Spry2 negatively regulate the 
survival and proliferation of CLL cells in part by attenuating MAPK-Erk and 
B-cell Receptor signaling pathways. 
 
 
 
17 
 
APPROACHES: 
Overview:  
Our main objective is to investigate the role of Spry2 in pathogenesis of CLL and 
to define the molecular mechanism leading to inhibition of proliferation and survival CLL 
cells. We would also like to demonstrate the molecular mechanism for SPRY2 
downregulation in CLL cells isolated from poor prognosis patients.  
To address this we have used primary CLL cells isolated from the peripheral 
blood of good prognosis and poor prognosis patients. We have used Mec-1 cells a CLL 
cell line showing features of constitutively active BCR and MAPK-Erk signaling (52). 
Mec-1 cells are wide used human CLL cell line. Mouse models of CLL have contributed 
hugely to our present understanding of the disease. To address our specific aims we 
used three mouse models. 1. CD19-CRE mouse model which directs the expression of 
cre recombinase specifically in B-cells (53). We will use these mice to direct Spry2 
expression only in B-cell. 2. Spry2 conditional transgenic mouse model, prior to CRE-
mediated deletion, the transgene expresses LacZ, while after cre mediated deletion a 
bicistronic mRNA containing both mouse Spry2 and human placental alkaline 
phosphatase (PLAP) coding sequence is expressed (54). 3. We will use NOD-SCID 
immunodeficient mice for xenograft mouse models. Using these reagents we have 
addressed four specific aims: 
AIM 1: To evaluate the role of Spry2 in CLL cell survival and proliferation:  
In this aim we hypothesize that Spry2 negatively regulates the proliferation and 
survival of CLL cells. To test this hypothesis we will manipulate the levels of Spry2 
expression in vitro and in vivo. Our working systems will help us in understanding the 
effect of Spry2 on the survival and proliferation of CLL cells. The transgenic mouse 
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model expressing Spry2 in B cells will provide valuable information for the role of Spry2 
in normal B cell development. We will use the following sub-aims to achieve the goals of 
this Aim. 
 
(a) To determine the effect of differential expression of Spry2 on primary CLL 
cells.  
In this sub-aim we hypothesize that increased expression of Spry2 
negatively regulates the survival and proliferation of primary human CLL cells. 
We used an IRB approved protocol to collect peripheral blood from good and 
poor prognosis CLL patients. We isolated CLL cells by negative selection using 
Miltenyi Biotech B-CLL cells isolation kit. We reconstituted the expression of 
Spry2 in primary CLL cells from poor prognosis patients using nucleofection as 
described previously (55). We used GFP coexpressing empty and Spry2-cDNA 
containing vector for transfection to primary patient CLL cells. Cells were 
analyzed by Annexin-V staining using Flow cytometry, 48 and 72 hours post 
transfection with respective vectors to determine the number of apoptotic cells. 
We also performed Spry2 knockdown in CLL cells using siRNAs from good 
prognosis patients and study their proliferation by Ki-67 staining.  
(b) To examine the role of Spry2 in CLL initiation and progression. 
 In this sub-aim we hypothesize that increased Spry2 expression in B1 
cells will delay CLL initiation and progression. B1 cells are the precursor cells of 
CLL in rodents. Based on our preliminary data and published literature, it 
appears that the ectopic expression of Spry2 decreases the viability of B cells 
and increases the apoptosis of CLL cells. In order to study the effect of Spry2 on 
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CLL initiation and progression we crossed the CD19-Cre mouse to Spry2 
transgenic mouse to generate Spry2 transgenic mouse expressing the transgene 
specifically in B cells (CD19cre-Spry2(tg)). We measured the absolute numbers 
of B1 cells and studied the proliferation of splenic B2 cells using CSFE labeling. 
We also used xenograft model of SPRY2 knockdown Mec-1 CLL cells to study 
SPRY2 role in CLL disease progression. 
 
AIM 2: To elucidate the mechanism through which Spry2 regulates 
proliferation and survival in CLL cells.  
 In this Aim we hypothesize that Spry2 negatively regulates the survival and 
proliferation of CLL cells by attenuating BCR and MAPK-Erk signaling pathways. To test 
this hypothesis we studied the effect of Spry2 on cells with constitutively active MAPK-
Erk and BCR. We used calcium influx assay in SPRY2 modified normal human B cells 
and splenic B2 cells from CD19cre-Spry2(tg) mice to study BCR signaling.  
(a) To investigate the effect of Spry2 induced expression on constitutively 
active MAPK and BCR signaling in vitro.  
We hypothesize that Spry2 will inhibit constitutive activity of MAPK-Erk 
and BCR signaling in CLL cells. There are several studies reporting mutations 
leading to constitutively active MAPK-Erk signaling pathways in CLL patients. To 
demonstrate this we used doxycycline inducible system where we reconstituted 
the expression of SPRY2 in Mec-1 cells upon doxycycline treatment. Expression 
of pErk was measured in those cells. To study the effect on BCR signaling we 
measured the expression of pSyk in SPRY2 reconstituted Mec-1 cells using 
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immune-fluorescence. This helped us in determining that the effect of Spry2 on 
hyperactive and genetically altered MAPK and BCR signaling. 
 
(b) To study the molecular mechanism through which SPRY2 downregulate 
BCR and MAPK-Erk signaling.  
We hypothesize that Spry2 will attenuate MAPK and BCR signaling by 
interacting with SYK, BRAF and RAF in CLL cells. To demonstrate this we used 
BRAF and KRAS mutants co-transfected with SPRY2 constructs. We also used 
immunoprecipitation and immunofluorescence to study the co-localization and 
interaction of SPRY2 with SYK, RAF and BRAF in CLL cells and normal human 
B cells.  In addition we used inhibitors to demonstrate the molecular mechanism 
through which SPRY2 downregulate survival and proliferation of CLL cells.  
 
AIM 3: To demonstrate the role of STAT3 in activating miR-21 to target 
Spry2 in CLL cells.  
In this aim we hypothesize that STAT3 induces the expression of miR-21 to 
inhibit Spry2 leading to activation of BCR mediated MAPK-Erk signaling in CLL cells. To 
demonstrate this we used stably pcDNA3.1-mir21 transfected Mec-1 cell line. For control 
we used stably transfected pcDNA3.1-Empty transfected and mec-1 cell line.  
(a) To investigate the effect of miR-21 on the expression of Spry2 in CLL cells.  
In this sub aim we hypothesize that high expression of miR-21 
suppresses Spry2 expression in CLL cells. To study this stably transfected Mec-1 
CLL cells with pcDNA-mir21 co-expressing GFP plasmid to upregulate mir-21 
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levels (54). After stable transfection, we measured the levels of miR-21 by 
performing qPCR. The protein levels of SPRY2, SYK and pErk were measured 
by using western blot. 
 
(b) To demonstrate that STAT3 activates miR21 in CLL cells.  
In this aim we hypothesize that STAT3 binds at miR21 promoter region to 
induce expression of miR-21 in CLL cells. To study this we stimulated STAT3 
expression by stimulating Mec-1 CLL cells with IL-10 and IL-6. We performed 
chromatin immunoprecipitation of STAT3 and studied the enhancement of miR21 
promoter region.  
(c) To determine the effect of miR-21 inhibition on Spry2 in human CLL cells.  
In this aim we hypothesize that miR-21 inhibition decreases the survival 
and proliferation by increasing Spry2 expression in primary human CLL cells. In 
this aim we will use primary CLL cells in vitro and Mec-1 CLL cells for testing 
anti-miR-21 and STAT3 inhibitors. To study the effect of miR-21 inhibition we 
used anti-miR-21 inhibitor, synthetic oligonucleotides designed to specifically 
bind and inhibit endogenous miRNAs from Ambion, Life Technologies (55). As 
miR-21 is overexpressed in CLL patients with poorer outcome we will use CLL 
cells from poor prognosis patients as described previously. We treated primary 
CLL cells from poor prognosis patients with STAT3 inhibitor, Stattic (CAS 19983-
44-9) from SantaCruz biotechnology. We used three different concentrations of 
2.5µM, 5µM and 10µM as previously described in other studies (ref). After 48 and 
72 hours post Stattic treatment cell viability was measured using MTT assay. For 
negative control we will use DMSO vehicle only. As miR-21 is upregulated in 
relapsed and/or refrectory CLL, we therefore, derived an Ibrutinib resistance CLL 
22 
 
cell line. To target MAPK signaling and miR-21 in these cells we treated Ibrutinib 
resistance cells with STAT3, MEK-1 and SYK inhibitors.  
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Chapter II 
Material and Methods:  
Isolation of CLL cells from patients and normal B-cells from healthy donors:  
Peripheral blood from CLL patients/healthy donors was obtained using UNMC approved 
IRB protocols. Mononuclear cells were isolated using Lymphoprep (StemCell technologies, 
Vancouver, Canada) following manufacturers instruction. CLL/normal B-cells (n-B cells) were 
isolated by negative selection using B-CLL cells /B-cell isolation kit Milteny Biotech San Diego, 
CA. Purity of the isolated CLL/n-B cells were tested by flow cytometry using CD19+CD5+/only 
CD19+ cell surface markers. When the CLL cell number was more than 90% in the peripheral 
blood from patients, the cells purification step was not performed. CLL patients with High CD38, 
unmutated IgV, Del 17p and Del 11q were categorized as poor prognosis, whereas CLL patients 
with Low CD38, mutated IgV and only Del 13q14.3 were categorized into good prognosis. 
Biological reagents and cell lines:  
Mec-1 cell line was kindly provided by Dr. Runqing Lu, UNMC. Mec-1 cells were cultured 
in RMPI media with 10%FBS, 1% pen strep and 1% L-glutamine (RF-10). Primary CLL cells were 
co-cultured on S-17 stromal cells in RF-10 media for apoptosis and proliferation experiments. 
Normal B cells were co-cultured on OP-9 stromal cells in RF-10 media.  
Antibodies:  
Antibodies for Spry2, BRAF, RAF-1, Syk were purchased from Santa Cruz 
Biotechnologies and antibodies for Spry2, p-Syk, p-Erk, Erk, PI3K, BTK and B-actin were 
purchased from Cell Signaling Technology. 
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Flow cytometry:  
Cells were washed with 1xPBS twice and resuspended in MACs buffer. Cells were stained 
with antibodies. Washed twice with MACs buffer and taken for flow analysis. For enumeration of 
apoptotic and proliferating cells Annexin-V (PE conjugated) apoptosis and Ki-67 proliefration 
assay (PE conjugated) kit was purchased from BD Biosciences, San Jose, CA. Cells were 
processed under manufacturer instructions. Flow cytometry was performed on FACSCalibur (BD 
Bioscience), using CellQuestPro software (BD Bioscience).  
Immunoprecipitation:  
Normal-B cells from healthy donor were stimulated by BCR crosslinking for 24 hours. Cells 
were with washed two times with 1X PBS and then re-suspended in ice cold 500µl of NP40 lysis 
buffer with protease and phosphatase cocktail inhibitor. After 30 minutes incubation on ice, 
Primary antibody was added and incubated overnight at 4C on shaker. Agrose beads were added 
and incubated for 2 hours at 4C on shaker. Beads were washed twice with NP40 lysis buffer, 
beads were mix with 1x SDS loading buffer dye boiled at 95C for 10 mins. Beads were removed 
and protein lysate was loaded on 10%SDS gel for protein analyses. 
Plasmids and Anti-sense:  
Spry2 cDNA plasmids were kindly provided by Dr. Hamid Band, UNMC. Spry2 cDNA was 
cloned in migR1 and TET-pLKO construct by using XhoI and EcoRI restriction enzyme site. 
pcDNA3.1-mir-21 plasmid (56) was purchased from Addgene, Cambridge, MA. pLenti-Spry2, 
pLenti-Empty, pLenti-scramble, pLenti-spry2siRNA(a) and pLenti-spry2siRNA(b) was purchased 
from ABM Goods, Richmond, Canada. Spry2 siRNAs were purchased from Invitrogen Life 
technologies Carlsbad, CA. 
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BCR crosslinking:  
Primary CLL cells and normal human B cells were stimulated with 5µg FCRII anti-IgM and 
anti-IgD antibodies (Sigma Aldrich, St. Lousi, MO) for different time points.  
Flow cytometry:  
Cells were washed with 1xPBS twice and resuspended in MACs buffer. Cells were stained 
with antibodies. Washed twice with MACs buffer and taken for flow analysis. For enumeration of 
apoptotic and proliferating cells Annexin-V (PE conjugated) apoptosis and Ki-67 proliefration 
assay (PE conjugated) kit was purchased from BD Biosciences, San Jose, CA. Cells were 
processed using manufacturer instructions. Flow cytometry was performed on FACSCalibur (BD 
Bioscience), using CellQuestPro software (BD Bioscience).  
Calcium mobilization assay:  
Human n-B cells from peripheral blood of healthy donor were isolated and murine B-cells 
were isolated from spleen by negative selection as previously described. Calcium influx assay 
was performed and analyzed as described by Ma et al. (57) 
Animal studies:  
CD19-rtTA-cre animals were kindly provided by Dr. Runqing Lu, UNMC. Spry2 conditional 
transgenic mouse (54) was purchased from MMRRC, UNC, Chapel Hill, NC. To generate 
CD19cre-spry2(tg) mice we crossed CD19-rtTA-cre and spry2(tg) flox/flox. Overexpression of spry2 
in B-cells was tested by western blot. Expression of spry2 was tracked by GFP positive cells in 
flow cytometry experiments. NOD-SCID gamma (NSG) mice were purchased from Jackson 
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Laboratory, Bar Harbor, ME. All animal experiments were conducted under the guidelines of 
approved IACUC protocols.  
Nucleofection:  
Primary B cells/ CLL cells were nucleofected with Spry2 cDNA plasmid or Empty using 
primary B cells kit, Lonza, Basel program U-16. Mec-1 cells were nucleofected using lonza 
solution V kit program X-01 (55).   
Western blot analysis:  
As previously described by us, western blotting was performed to analyze protein 
expression (58). Antibodies for Spry2, BRAF, Raf-1, Syk were purchased from Santa Cruz 
Biotechnologies, Dallas, TX and whereas antibodies for Spry2, p-Syk, p-Erk, Erk, PI3K, BTK  and 
B-actin were purchased from Cell Signaling Technology, Beverly, MA.  
Statistical Analysis:  
All data reported in graphs are expressed as SD+, p values were calculated by T-Test and 
were considered statistically significant when less than 0.05. All experiments were repeated at 
least 3 times unless specified.  
Ki-67 proliferation assay:  
 Cells were harvested and fixed with 2% PFA for overnight. Add 1ml 70% - 80% 
ethanol/methanol dropwise into the cell pellet (1-5 x 107 cells). Cells were incubated on ice for at 
least 1 hour. These fixed cells were then washed twice with 30-40 ml MACS buffer, centrifuge for 
10 minutes at 200 x g. Cells were then resuspended to a concentration of 1 x 107/ml. Transfer 
100 µl (1 x 106 cells) cell suspensions into each sample tube. Add 20 µl of properly diluted PE 
conjugated anti-Ki-67 antibody (BD Bioscience) according to the protocol into the tubes above. 
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Cells were mixed gently. Incubate the tubes at room temperature (RT) for 20-30 minutes in the 
dark. Cells were then washed with 2 ml of staining buffer at 200 x g for 5 minutes. Aspirate the 
supernatant. Wash with 2 times with MACS buffer. Add 0.5 ml of staining buffer to each tube. 
Proceed to flow cytometric analysis. 
DNA-Cell Cycle Analysis and Apoptosis Evaluation Telford Method 
 DNA analysis was performed by staining the cells with propidium iodide, a fluorescent dye 
which intercalates between DNA base pairs.  The fluorescent intensity of the dye within the 
nucleus is directly related to the amount of DNA present.  Normal cells contain a diploid DNA 
content (2N) where N is equal to the number of chromosomes in a normal haploid gamete.  Tumor 
cells often demonstrate abnormal DNA content.  Aliquot 1 x 106 cells into a 12x75 mm test tube.  
Pellet the cells in the benchtop Immufuge for 1 min on “High”. Decant the supernatant and add 1 
ml of 70% ethanol.  Mix well and incubate at 4o C or on ice for 1 hour.  Spin down for 1 min and 
decant ethanol.  Wash 1X with 1 ml of PBS and spin down.  Add 1 ml of Telford reagent (DNA 
stain for ethanol fixed cells).  Incubate at 4o C overnight or for at least 30 min.  Analyze by flow 
cytometry. Cells were incubated overnight at 4o C to allow better intercalation of the PI and 
diffusion of small DNA fragments to diffuse from the cells. 
Immunofluorescence staining of cells. 
Cells were harvested and cytospins were prepared. By adding 4% PFA for half an hour 
cells were fixed.  Gently, perform two washes with 0.1M Glycine for 5 mins. Permeabilize the cells 
by adding Permeabilization Buffer drop wise for half an hour.  After permeabilization cells were 
blocked by adding blocking Solution for half an hour. Incubate cells in primary antibody in 10% 
goat serum or 5%BSA overnight at 4C (or one hour for 37C). Wash cells three times with 1/10 
permeabilization buffer in PBS for 10 mins. Incubate cells with secondary antibody in 10% Goat 
serum or 5%BSA for 40 mins to 1 hour at room temperature (or 37C).  
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Cells were washed three times with permeabilization buffer in PBS for 10 mins. Followed by one 
wash with 1/10 permeabilization buffer in PBS.  Cells were then stained with DAPI for 5 minutes. 
Mount the cells with Mounting Media. These slides were then analyzed in immunofluorescence 
microscope and the expression of proteins were determined by the fluorescence intensity of 
specific protein antibodies. 
 
RNA isolation using Trizol  
Cells were harvested and washed twice with 1 x PBS. Add at least 1ml of TRI ReagentTM 
(Invitrogen, CA) per 10 million cells to resuspend. (If the cells are more or you see cloudy particles 
in tube split it into two and add more trizol). Mix well and incubate at room temperature for 5 mins. 
Add 300ul of chloroform and mix by inverting the tube for 15-20 secs. Set the tubes for 5 mins at 
room temperature. Centrifuge the sample at 12,000 rpm at 4C for 15 mins.  Extract the clear upper 
supernatant (do not disturb the cellular layer) and put it in a fresh tube. Add 500ul isopropanol 
and 1ul of glycogen (RNA graded from invitrogen). You can stop at this step and store the samples 
at -80C. Keep the samples at room temperature for 5 mins. Spin for 10 mins @ 12000 rpm at 4C.  
Decant the supernatant and add 1ml 75% ethanol and mix and spin @ 7500rpm for 5 mins. 
Decant the supernatant and air dry for 5-10 mins. Re-dissolve in 20ul of ddH2O. Store RNA at -
80C or process it for cDNA immediately.  
Quantitative Real Time PCR 
Total RNA from cells was extracted and purified using TRI ReagentTM as described above. 
Five micrograms of total RNA was then used for reverse transcription by using random hexamer 
primers and the superscript RT enzyme (Invitrogen, CA). The resulting cDNA was subjected to 
SYBR green real-time PCR to investigate the differential expression of genes. The cDNA was 
mixed with primers and SYBR green PCR master mix (Applied Biosystems, CA), and real-time 
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PCR was performed using the ABI Prism-7900HT real-time PCR detection system (Applied 
Biosystems, CA). The PCR reaction consisted of 36 cycles of 30 seconds at 95oC, then 30 
seconds at 60oC, and finally 30 seconds at 72oC. Cycle threshold (Ct) values were used to 
determine fold changes in expression and compared among treatment groups after being 
normalized with GAPDH.  
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Chapter III 
SPROUTY2: A novel regulator of B cell receptor and MAPK 
signaling pathways in CLL.  
Introduction:    
Precise regulation of cellular processes, such as those mediated by B-cells, 
requires homeostatic integration between intrinsic and extrinsic factors (59). Deregulation 
of such homeostatic processes in CLL cells could result in a state of constitutive activation 
of MAPK-Erk and BCR signaling. Constitutive activation of BCR and MAPK-Erk signaling 
promotes CLL cell survival and proliferation (12-14,18). However, the molecular 
mechanisms that lead to the constitutive activation of these pathways have not been fully 
explored. Identifying novel regulators of these pathways in CLL is crucial for understanding 
the disease biology and for the eventual development of targeted therapies.  
To identify potential regulators of BCR and MAPK-Erk signaling in CLL, we 
performed a transcriptome analysis for genes that are differentially expressed in CLL 
patients with good vs poor prognosis. Of interest in relationship to MAPK-Erk signaling, 
we observed that expression of Sprouty-2 (SPRY2), a member of the sprouty protein 
family to be significantly down-regulated in CLL cells from poor prognosis patients 
compared to those from good prognosis patients. Sprouty proteins play key roles in 
maintaining cellular homeostasis by attenuating signaling, including MAPK-Erk pathway, 
downstream of several receptor tyrosine kinases (RTKs) (22-26). Notably, none of the 
other Sprouty family members (SPRY1, 3 and 4) showed significant differences in 
expression between the good and poor prognosis CLL cells. Therefore, we hypothesized 
that low levels of Sprouty 2 lead to a state of constitutive activation of BCR and MAPK-
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Erk signaling in CLL patients with poorer clinical outcomes. Mechanistically, SPRY2 
functions as an inhibitor of the ligand-induced RTK signaling. In addition, tyrosine 
phosphorylation of SPRY2 creates SH2 domain-binding motifs that are critical for its 
recruitment to signaling complexes at the plasma membrane and attenuation of signaling 
cascades triggered by membrane associated RTKs (22, 27). Therefore we reasoned that 
SPRY2 might act as a negative regulator of BCR signaling to inhibit the survival and 
proliferation of CLL cells. Consistent with such a possibility, a recent study demonstrated 
the induction of SPRY2, but not SPRY1, downstream of BCR signaling in mouse B-cells 
(32). This study also showed that SPRY2 levels negatively correlate with Erk signaling in 
mouse B cells, a finding similar to that described in other cellular systems (22-26, 32, 33). 
However, the molecular mechanism by which SPRY2 functions as a negative regulator of 
BCR signaling has not been deciphered. Moreover, the role of SPRY2 in B cell 
development and function are unknown. SPRY2 was previously shown to be down-
regulated in Diffuse Large B cell Lymphoma but the functional significance of this down-
regulation remains ambiguous (32).  
In the present study, we identify SPRY2 down-regulation as a marker of poor 
prognosis in CLL and demonstrate that loss of SPRY2 provides a novel mechanism to 
constitutively activate BCR and MAPK-Erk signaling in CLL. Along with RAF and BRAF 
we have identified spleen tyrosine kinase (SYK) as a novel interacting partner of SPRY2 
in normal B cells and CLL cells. We have also defined a novel role for SPRY2 as a negative 
regulator of BCR signaling. This result highlights a potentially complex role for sprouty 
proteins in cancer from distinct activities as either tumor suppressors. Finally, we show 
that SPRY2 is targeted by miR-21 in poor prognosis CLL that leads to constitutive activate 
state of BCR and MAPK-Erk signaling in CLL cells. 
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Results:  
Spry2 expression is lower in CLL cells from poor prognosis patients compared to 
good prognosis patients:  
CLL is clinically heterogeneous, with varying clinical outcomes and possibly 
distinct molecular pathogenesis. In order to identify molecular mechanisms associated 
with the poor prognosis form of CLL, we performed RNA-sequencing based transcriptome 
analysis of 15 CLL samples: 7 from good prognosis and 8 from poor prognosis patients. 
Poor prognosis patients were defined by un-mutated immunoglobulin heavy chain variable 
(IgVH)-segments, 11q22 deletion, 17p deletion, trisomy 12 and/or high CD38 expression. 
Good prognosis patients were defined as having mutated IgVH, 13q14 deletions and/or 
low CD38 expression (criteria used for Figure1-A, B and C). This method allowed us to 
simultaneously identify recurrent mutations and differential gene expression. We validated 
the differentially expressed genes using gene expression profiling data from a separate 
cohort of 38 CLL patients. Using these approaches, the expression levels of 146 genes 
were found to be significantly different between good versus poor prognosis CLL samples. 
We further selected genes based on their roles in B cell biology, or for their putative tumor 
suppressor or pro-oncogenic functions. Interestingly, spry2 was found to be significantly 
(3.4 log2-fold) down-regulated in the CLL cells from poor prognosis patients compared to 
those from good prognosis (Figure 1A). The differential expression was confirmed using 
western blotting and real time PCR of CLL cells from good vs. poor prognosis patients 
(Figure 1B & C). High CD38 positivity of CLL cells is associated with poor patient outcomes 
and constitutive activation of MAPK-Erk signaling (60). Therefore, we further compared 
spry2 expression in a larger cohort of 38 patients. Spry2 was significantly down-regulated 
(~2.8 folds) in CLL cells of patients with high CD38 expression compared to those with 
low CD38 expression (Figure 1D). We also observed low Spry2 mRNA expression in CLL 
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cells isolated from patients with unmutated IgVh and Del 17p when compared those from 
patients with mutated IgVh and Del 13q (Figure 1E & F). As CLL is clinical heterogeneous 
disease we also studied the expression of SPRY2 in a larger cohort of primary CLL cells 
in the study using Oncomine database and observed significant reduction in SPRY2 
expression when compared with normal B cells. (Figure 1G).  
As microenvironment plays a critical role in the survival of CLL cells. Indeed, the 
lymph node microenvironment is able to promote B-cell receptor signaling and tumor 
proliferation in CLL. In this respect, to study the effect of stromal co-culture of primary CLL 
samples on SPRY2 expression we co-cultured primary CLL cells on S-17 stromal cells 
and CLL cells alone. However there was no effect on SPRY2 levels in culturing CLL-cells 
alone vs CLL-cells co-cultured on S-17 cells (Figure 1H). Nevertheless, SPRY2 levels are 
much lower in CLL-cells isolated from bone marrow when compared with the CLL-cells 
isolated from peripheral blood from same patients as shown in Figure 1I. These results 
highlights that deregulation of Spry2 in CLL cells in CLL tumor microenvironment. 
Whereas examination of the expression of other sprouty family members (SPRY1, 3 and 
4) in our data-set showed that, none of them were significantly differentially expressed 
between the good and poor prognosis CLL cells (data not shown). Thus our results show 
that the expression of SPRY2 is significantly down-regulated in CLL cells from patients 
with poor outcomes. 
SPRY2 is induced upon BCR cross-linking of normal B-cells and CLL cells, and 
functions as a negative regulator of BCR signaling:  
It is well established that BCR signaling is critical for survival and proliferation of 
CLL cells, however; no known recurrent mutations have so far been identified in this 
pathway among CLL patients. It has been established that SPRY2 functions as a negative 
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feedback regulator of RTKs (22-36). To investigate if SPRY2 is regulated by BCR 
signaling, we stimulated normal B cells from healthy donors and CLL cells from patients 
using BCR crosslinking with an anti-IgM/IgD antibody. Cells were collected at 0, 6, 12, 24 
and 48 hours after stimulation and the expression of SPRY2 was determined by western 
blotting. We observed a gradual increase over time in SPRY2 expression in BCR 
stimulated normal B-cells (Figure 2A upper panel). On the other hand, primary CLL cells 
and Mec-1 CLL cell line exhibited a biphasic induction of SPRY2 (Figure 2A middle and 
lower panels). In CLL cells, SPRY2 expression peaked at 12 hours upon stimulation and 
declined at later time points (Figure 2A middle and lower panels). Thus, we conclude that 
SPRY2 expression induced by BCR crosslinking is sustained in normal B-cells but follows 
a cyclical expression pattern in CLL cells and is not sustained.  
We next studied the effect of downregulating SPRY2 expression with siRNAs on 
BCR signaling in normal B cells obtained from healthy donors. We first tested the siRNAs 
in B cells. Compared to the scramble siRNA control, both SPRY2 siRNAs led to a 
decrease in the SPRY2 protein levels, but siRNA-B was more robust compared to siRNA-
A (Figure 2B). Next, we transfected normal B-cells with the scrambled control or SPRY2 
specific siRNAs and compared their anti-IgM-induced calcium influx with that of 
unperturbed control following with the Indo-1 dye. Compared to un-transfected and 
scrambled siRNA controls, B-cells with SPRY2 knockdown exhibited elevated calcium 
influx (Figure 2C). Even the basal levels of calcium were increased in B cells with SPRY2 
knockdown. Taken together, these results establish that SPRY2 functions as a negative 
regulator of BCR signaling. 
 
35 
 
SPRY2 depletion in human CLL cells from Good Prognosis patients lead to 
increased proliferation.  
As an approach to assess if the down-regulation of SPRY2 expression in poor vs 
good prognosis CLL cells is of functional consequence, we examined the impact of SPRY2 
depletion in good prognosis CLL cells. For this purpose, we isolated CLL cells from newly-
diagnosed patients with good prognosis CLL based on low CD38 expression, Del 13q 
and/or normal karyotype. We also used Mec-1 human CLL cell line, a widely-used cultured 
CLL cell model, for these studies. Mec-1 cells have an intermediate level of SPRY2 
expression relative to primary good and poor prognosis CLL cells, as detected by western 
blotting (Figure 2A). As SPRY2 expression is induced on CLL cells upon BCR stimulation 
(Figure 2A), we assessed the impact of SPRY2 depletion on anti-IgM or anti-IgD induced 
Mec-1 cell proliferation, by analyzing changes in Ki-67+ fraction in FACS analyses. SPRY2 
knockdown led to an increase in proliferation of Mec-1 cells relative to scrambled siRNA 
control under both anti-IgM and anti-IgD cross-linking condition (Figure 3A). Next, we 
transfected primary human CLL cells isolated from multiple good prognosis patients 
expressing higher levels of SPRY2 with siRNAs against SPRY2. 24 hours post 
transfection, the cells were subjected BCR cross-linking and level of proliferation was 
assessed 48 hours later. Knockdown of SPRY2 led to an increase in the number of 
proliferating cells compared to the scrambled siRNA transfected cells (Figure 3B, C & D). 
We confirmed this finding in CLL cells isolated from peripheral blood of 7 different CLL 
patients. We observed an increase in proliferation upon SPRY2 depletion compared to 
scrambled controls, with increased proliferation seen in 6 out of 7 with siRNA-B and in 5 
out of 7 cases with siRNA-A mediated knockdown. The effect on proliferation were 
consistent with a more robust SPRY2 knockdown with siRNA-B with siRNA-A. We also 
measured the extent of apoptosis in these samples by Annexin-V staining, but we did not 
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observe significant differences between control and SPRY2 knockdown cells (data not 
shown). These findings indicate that SPRY2 functions as a key negative feedback 
regulator of BCR signaling in CLL cells and involved in limiting their BCR induced 
proliferation.  
SPRY2 expression induces apoptosis in human CLL cells from poor prognosis 
patients:  
To further elucidate the underlying basis for the down-regulation of SPRY2 
expression in CLL cells from poor prognosis patients, we also examined the impact of 
ectopic SPRY2 expression on CLL cells with low SPRY2 expression. First, we examined 
the impact of increasing the expression of SPRY2 in Mec-1 cells, which express 
intermediate levels of SPRY2. We transfected Mec-1 cells with a SPRY2 expression 
construct that co-expresses a GFP as a reporter of transfection. At 48 and 72 hours post 
transfection, we observed an average of 58% and 18% of SPRY2 expressing (GFP+) Mec-
1 cells to be Annexin V positive, respectively, compared to, 36% and 11% (Figure 4A & 
B). Next, we isolated CLL cells from five different poor prognosis patients, ectopically 
expressed Spry2 in these cells and measures the proportion of Annexin V staining cells 
after 48 hours (Figure 4C). An increase in apoptosis was observed in CLL cells from all 
five patients, SPRY2 as a negative regulator of CLL cell survival (Figure 4C & D). 
Moreover, we did not observe a significant impact on the proliferation of these cells 
compared to controls. Thus, our results demonstrate that low levels of SPRY2 in Poor 
prognosis patients CLL cells contribute to a survival advantage for cells.  
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B-cell-specific elevation of SPRY2 levels attenuates and suppresses B1 cells 
population:  
To study the effect of SPRY2 on the development and function of B-cells in vivo 
we generated a B-cell-specific SPRY2 transgenic mouse model. For this purpose, we 
crossed the mice harboring a spry2 transgene preceded by a STOP cassette (Spry2(tg)) 
with mice carrying a CD19rtTa-cre transgene to obtain a mouse line (CD19-cre;Spry2(tg)) 
in which the expression of cre recombinase expression and hence SPRY2 expression are 
specifically induced in B-cells (Figure 5A). We observed that the generation of B-cells in 
these mice was apparently normal (Figure 5B). However, we observed a decrease in the 
number of a specialized B cell subset known as B1 cells in the CD19-cre;Spry2(tg) mice. 
This was particularly interesting because B1 cells are presumed to serve as precursors of 
CLL cells in mouse models of CLL. We found a decrease in the percentage of B1a (B220+ 
CD5+) cells in the peritoneal cavity of these mice (Figure 5C). Furthermore, we examined 
the effect of SPRY2 overexpression on BCR signaling in B-cells of CD19-cre;Spry2(tg) 
mice, compared to CD19-cre control mice by measuring their calcium influx over time in 
response to BCR cross-linking. The calcium influx in B-cells from CD19-cre;Spry2(tg) mice 
showed was significantly reduced compared to B cells isolated from CD19-cre control 
mice (Figure 5D). To study the effect of SPRY2 overexpression on proliferation, we 
isolated splenic B-cells from CD19-cre;Spry2(tg) mice labeled these with the CFSE dye 
and cultured the cells with and without anti-IgM antibodies. Strikingly, we detected very 
few or no cells undergoing division in CD19-cre;Spry2(tg) compared to CD19-cre control 
cells with or without BCR stimulation (Figure 5E). Taken together, these results show that 
Spry2 functions to limit the numbers of B1 cells (CLL precursors) in mice and negatively 
regulates BCR signaling and associated proliferation in mouse B-cells. 
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SPRY2 depletion in CLL cells results in more rapid lymphomagenesis in NSG mice:  
In view of the effect of SPRY2 on the survival and proliferation in vitro, as well as 
its impact in regulating B1 pool of mouse B-cells, we modeled the low SPRY2 expression 
seen in human CLL disease in a mouse lymphomagenesis model. For this purpose, we 
used a xenograft model with Mec-1 CLL cells transplanted into NOD-SCID-Gamma chain 
deficient (NSG) mice. We derived SPRY2 knockdown version of Mec-1 cells by 
transducing them with pLenti-siRNA(A) or pLenti-siRNA(B), with pLenti-scramble siRNA 
(pLenti-scr) Mec-1 cell line as a control. Proliferating cell populations were measured by 
Ki-67 staining. We observed about 30% or 32% increase in proliferation of the pLenti-
siRNA(A) and pLenti-siRNA(B) cell lines, respectively, when compared with the pLenti-scr 
cell line (Figure 6A). We also observed a significant decrease in the percentage of cell 
exhibiting apoptosis in pLenti-siRNA(A) and pLenti-siRNA(B) cell lines, compared to 
scrambled control (Figure 6B). Next, we injected 1.5x106 pLenti-siRNA(B) (higher degree 
of SPRY2 down-regulation) or pLenti-scr expressing Mec-1 cells subcutaneously into the 
left flank of sublethally irradiated NSG mice (5 mice per group). Tumors were palpable 
after 21 days of cell injections. Measurement of tumor volume using caliper demonstrated 
that pLenti-siRNA(B) Mec-1 cells gave rise to significantly larger tumors at the primary site 
of cell injection (Figure 6C&D). Dissemination of human CLL cells into other organs was 
measured by anti-human CD19 flow cytometry analysis. We observed significantly more 
human CD19 positive CLL cells in spleens of pLenti-siRNA(B) Mec-1 cell-injected mice 
(Figure 6E). Measured by H&E staining of spleen, liver and kidney also revealed more 
organ infiltration in pLenti-siRNA(B)-expressing CLL cells (Figure 6F). Western blot 
analysis of tumor isolated from NSG recipient mice confirmed the continuous down-
regulation Spry2 in pLenti-siRNA(B) cell line-derived tumors compared to scrambled 
control cell line-derived tumors (Figure 6G). Furthermore, we also observed an increase 
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in pERK levels in tumors arising from SPRY2-depleted Mec-1 cells (Figure 6G). These 
results show that lower SPRY2 expression leads to the formation of more rapid and 
aggressive lymphomagensis in mice, indicating a role for SPRY2 down-regulation in CLL 
disease progression. 
 
Spry2 interacts with Raf-1, Braf and Syk to down regulate MAPK-Erk signaling in 
CLL cells.  
To elucidate the mechanism by which SPRY2 mediates a decrease in proliferation 
and survival of human CLL cells, we used a tet-on inducible system. We stably transfected 
Mec-1 cells with spry2 under the control of a tet-on promoter. Upon doxycycline treatment, 
we observed a dose-dependent increase in SPRY2 expression that was accompanied by 
a decrease in pERK levels (Figure 7A). Other groups have shown that SPRY2 interacts 
with Raf-1 and Braf to inhibit MAPK-Erk signaling in malignancies such as multiple 
myeloma (48-50). Interestingly, mutations in Raf-1 and Braf have also been identified in 
CLL patients (15). We first tested the conservation of these networks in human B-cells 
using immunoprecipitation of SPRY2 in BCR stimulated normal B-cells from healthy 
donors. Immunoprecipitation of SPRY2 in lysates of human B-cells led to co-
immunoprecipitation of Raf-1 and Braf in suggesting that SPRY2 may attenuate MAPK-
Erk signaling by inhibiting Raf-1 and Braf activities. 
We next tested the effect of SPRY2 on MAPK-Erk signaling in the presence of Braf 
and Ras mutants. It has been demonstrated that Braf V600E mutant harboring a valine to 
glutamic acid substitution does not physically interact with SPRY2 and is resistant to 
SPRY2-mediated attenuation of MAPK-Erk signaling (50). Additionally, Ras mutants 
function upstream to Raf and can bypass SPRY2 mediated inhibition (51). Therefore, we 
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tested the effect of SPRY2 on these mutants in human CLL cells. Intriguingly, SPRY2 
expression led to a decrease in p-Erk expression level even in the presence of BRAF 
V600 mutant however, while there was no impact of inducing SPRY2 expression on p-Erk 
level in cells transfected with the Kras V12 mutant (Figure 7B). These results indicate an 
additional and possibly parallel mechanism by which SPRY2 may attenuate MAPK-Erk 
signaling in B cells and CLL cells. 
Interestingly, a recent study showed that in the presence of BRAF inhibitors, Syk 
undergoes upregulation to activate Erk signaling in CLL cells, an event mediated via Ras 
(61).  Furthermore, inhibition of Syk reversed the Erk hyper-activation and led to a 
decrease in proliferation of CLL cells (61). Therefore, we speculated that SPRY2, in the 
presence of Raf inhibition may also inhibit Syk activity in B cells and CLL cells to attenuate 
MAPK-Erk signaling. To test this hypothesis we performed immuno-precipitation assays 
in stimulated normal B cells from healthy donors. Intriguingly, SPRY2 was found to 
physically interact with Syk but not with Bruton’s Tyrosine kinase (BTK) and PI3K in B 
cells as determined by reciprocal immuno-precipitation experiments (Figure 7C). Also, 
using immunofluorescence analysis, we observed a co-localization of SPRY2 with p-Syk 
in normal B cells and Mec-1 CLL cells (Figure 7D). We next tested the effect of SPRY2 
overexpression on the activated form of Syk by measuring the levels of p-Syk in splenic 
B-cells from CD19-cre;Spry2(tg) mice and SPRY2 overexpressing Mec-1 cells by 
immunofluorescence. Notably, we observed a decrease in p-Syk expression in B-cells of 
CD19-cre;Spry2(tg) mice and Mec-1 cells overexpressing SPRY2 compared to B cells 
from CD19-cre  mice  and Empty vector Mec-1 cells, respectively (Figure 7E& F). We also 
observed a synergistic effect of SPRY2 with BRAF and Syk inhibitors in the presence of 
BRAF-V600 mutant, again highlighting the dual mechanism through with SPRY2 
downregulates MAPK-Erk signaling in CLL cells (Figure 8). Thus, our results demonstrate 
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that Spry2 attenuates BCR mediated MAPK-Erk signaling by simultaneous inhibition of 
Raf and Syk activity in B cells and CLL cells. 
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Figures and Tables:  
Figure 1 
 
Comparison of SPRY2 levels in CLL cells from Good and Poor Prognosis patients. 
To compare the expression of SPRY2, CLL cells were isolated from PB of good and poor 
prognosis patients. (A) Relative mRNA level of spry2 from transcriptome analyses of 7 
good prognosis and 8 poor prognosis CLL patients (n=15). RNA isolated from PB CLL 
cells was used for sequencing. The expression was normalized with GAPDH and genomic 
reference DNA was used as control for transcriptome analysis. (B) Real time-PCR 
measurement of relative expression of spry2 in CLL cells from good and poor prognosis 
patients, normalized with GAPH. (C) Levels of SPRY2 protein expression was measured 
in good prognosis patients (n-5) and poor prognosis patients (n=5). Displayed is a scanned 
western blot and densitometric measurements showing reduced protein levels of SPRY2 
in poor prognosis CLL patients.  
43 
 
 
 
Mononuclear cells from healthy donor were used as positive control for antibody. 50µg of 
protein was loaded on 10%SDS gel. Beta actin is used as loading control. (D) Microarray 
data showing low relative expression of SPRY2 in patients with high CD38 expression. 
Patients with more than 30% of CD38 positive cells were considered CD38 High (n=15) 
and patients with less than 30% were considered Low CD38 (n=23) GAPDH was used to 
normalize the value, * p value=0.0045. (E) Shows SPRY2 mRNA levels in CLL cells from 
patients with IgVh unmutated vs mutated, n=18 p=0.0067. (F) Shows SPRY2 mRNA levels 
in CLL cells from patients with Del 17p vs Del 13q, n=20, p=0.0045. 
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(G) Shows the comparison of SPRY2 mRNA levels in primary CLL cells vs peripheral 
blood, this data was obtained from oncomine data set. Haferlach leukemia comparison of 
CLL (n=448) vs peripheral blood mononuclear cells (n=74) published in J Clin Oncol 
2010/05/20. 
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(H) Shows the no change in the levels of SPRY2 when cultured alone vs cultured on S-17 
stromal cells in vitro. (I) Shows SPRY2 mRNA levels from in CLL cells isolated from paired 
Bone Marrow and Peripheral Blood from same patients n=4, P=0.03. 
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FIGURE2.  
 
Effect of SPRY2 on BCR signaling. To study the role of SPRY2 in CLL and normal B-
cells, we isolated CLL and normal B cells from patients and healthy donors respectively. 
(A) Normal B-cells, primary human CLL cells and Mec-1 CLL cells were stimulated by 
BCR crosslinking for 0, 6, 12, 18, 24 and 48 hours. Cells were washed and protein lysate 
was prepared. Protein level of SPRY2 was determined by western blotting. First panel 
shows SPRY2 levels in normal B-cells, Second Panel shows SPRY2 levels in primary CLL 
cells from patient and third panel shows SPRY2 levels in Mec-1 CLL cells. (B) To test the 
efficacy of siRNAs against SPRY2 Normal B cells were transfected with siRNAa and 
siRNAb after 48 hours of transfection cells were washed and lysate was prepared.  
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Equal amount of protein was loaded in each well, Scramble siRNA and β-actin was used 
as control. Displayed is scanned western blot showing decrease in SPRY2 levels after 
siRNAs treatment. (C) Normal B-cells were isolated from healthy donors and nucleofected 
with scramble, siRNA A and siRNA B. After 48 hours of calcium influx assay was 
performed using Indo-1 dye dots represent 20 second time intervals. Displayed is mean 
graph of Indo-1 violet/Indo-1 Blue ratio, n=5 normal B cells samples from different healthy 
donors and p=0.0001.  
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FIGURE3.  
 
Knockdown of SPRY2 increases proliferation of CLL cells from Good prognosis 
patients. To determine the effect of SPRY2 knockdown on human CLL cells we used 
Mec-1 cells and primary CLL cells from Good Prognosis CLL patients. (A) Displays mean 
bar graph of 3 repeats showing Ki-67 staining of Mec-1 cells after SPRY2 knockdown with 
anti-IgM and anti-IgD antibody stimulation. (B) Dot plot of patient’s sample CLL-1showing 
increase in proliferation after SPRY2 knockdown using two different siRNA.  
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(C) CLL cells were isolated from peripheral blood of n=7 different good prognosis CLL 
patients. CLL cells were nucleofected with scramble, siRNA a and siRNA b and co culture 
on S-17 stromal layer. After 48 hours CLL cells were stained with Ki-67 stain and 
proliferation was measured. Displayed bar graph is fold in the rate of proliferation of CLL 
cells. (D) Displays the mean fold change of (C) showing significant p=0.01 increase in 
proliferation after SPRY2 knockdown with siRNA b.   
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FIGURE 4 
 
 Expression SPRY2 induces spontaneous apoptosis in CLL cells. (A) Mec-1 cells 
were transfected with Empty and spry2-cDNA GFP co-expressing vectors. (B) This figure 
shows Annexin-V staining done after 48 and 72 hours. Only live cells were gated for the 
analysis. The numbers represent the percentage of GFP positive cells also positive for 
Annexin-V.  
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(C) Primary CLL cells from n=5 different Poor Prognosis CLL patients were nucleofected 
with spry2-cDNA and Empty vector. Bar graph represents fold in percentage of apoptotic 
cells. (D) Mean Fold change of spry2-cDNA and Empty vector transfected cells from fig 
(C) p=0.009.  
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FIGURE5.  
 
 
Effect of SPRY2 on B1 cell development and BCR signaling in murine model. (A) 
Displayed is a western blot showing overexpression of spry2 in splenic B-cells of CD19-
cre;Spry2(tg). (B) Splenocytes from CD19creSpry2(wt) and CD19creSpry2(tg) mice were 
isolated and stained with anti-IgD and anti-IgM to study marginal zone and follicular B cells 
population. IgMhighIgDint shows marginal zone B cells and IgMintIgDhigh demonstrate 
follicular B cells. (C) B1-cells were isolated from peritoneal cavity of CD19-cre;Spry2(wt) 
and CD19-cre;Spry2(tg) mice. B1-cells were stained with CD5 and B220 dye to determine 
the frequency of B1-cells using Flow cytometric analysis. Displayed is dot plot of showing 
B1a-cells frequency in CD19-cre;Spry2(wt) and CD19-cre;Spry2(tg) mice. Bar graph of 
absolute number of B1a-cells in peritoneal cavity of CD19-cre;Spry2(wt) and CD19-
cre;Spry2(tg).  
53 
 
 
(D) Splenic B-cells were isolated by negative selection from rTTA positive CD19-
cre;Spry2(wt) and CD19-cre;Spry2(tg) mice. GFP+ population displays CD19-cre 
expressed cells and displayed is calcium mobilization assay of splenic B-cells from above 
described mice n=3; p=0.0002. (E) Splenic B-cells were isolated from CD19-cre;Spry2(wt) 
and CD19-cre;Spry2(tg) stained with CFSE dye and cultured in vitro for six days with and 
without anti-IgM antibody.  Displayed is the CFSE labeling of splenic B-cells of CD19-
cre;Spry2(wt) and CD19-cre;Spry2(tg) mice. 
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FIGURE6 
  
SPRY2 knockdown leads to disease progression in NSG mice.  
SPRY2 was stably knockdown in Mec-1 CLL cells using pLenti-siRNA A and pLenti-siRNA 
B, pLenti-scramble were used as control. (A) Displayed represents the mean bar graph of 
3 repeats of propidium iodide to study the number of apoptotic cells in pLenti-scramble, 
pLenti-siRNA A and pLenti-siRNA B cell lines. (B)  Displayed mean bar graph of 3 repeats 
of Ki-67 positive cells measured by flow cytometric analyses Mec-1 cells after pLenti-
scramble, pLenti-siRNA A and pLenti-siRNA B stable transfection. 
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(C) Displayed average of tumor volume in n=5 mice in each group were transplanted with 
1.5 million pLenti-scramble and pLenti-siRNA B Mec-1 CLL cells. Tumor volume was 
measured, using digital caliper we determine the length and width of the tumor. Tumor 
volume was calculated by V = (L x W x W)/2 where V is the tumor volume, L is the tumor 
length and W is the width of the tumor. (D) Displays the tumor and spleen pictures from 
pLenti-scramble and pLenti-siRNA B cell line transplanted NSG mice. (E) Represents the 
frequency of Human CD19 positive cells in spleen of pLenti-scramble and pLenti-siRNA 
B CLL cells transplanted mice.  
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(F) Shows the hemotoxilin and eosin staining with tissue section of Kidney, Liver and 
Spleen to observe the number of CLL cells infiltration in pLenti-scramble and pLenti-siRNA 
B CLL cells transplanted mice. (G) Protein lysates were prepared from tumors; equal 
amount of protein was loaded in each lane of 10%SDS gel. Shown is scanned western 
blot to determine the protein levels of p-Erk and SPRY2 in tumors from pLenti-scramble 
and pLenti-siRNA B CLL-cells transplanted mice. Total Erk and β-actin were used as 
control. Densitometric measurements showing elevated of p-Erk normalized by total Erk 
in SPRY2 knockdown tumors.  
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FIGURE 7 
 
 
SPRY2 downregulate MAPK-ERK signaling by interacting with RAF-1, Syk and 
BRAF. (A) Mec-1 cells were transfected with pLKO-TET-Empty and pLKO-TET-Spry2, 
Cells were treated with doxycycline for four days to induce the expression of SPRY2. 
Displayed is a scanned western blot of CLL cells transfected with Empty and spry2 cDNA 
to measure the protein levels of SPRY2 and p-Erk upon doxycycline treatment. β-actin 
and PAN Erk1/2 were used as controls. (B) KRAS-V12 and BRAF-V600 mutants were co-
transfected with Empty and Spry2 vectors in Mec-1 cells. Scanned western blot showing 
the p-Erk and Erk levels in these cells.  
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Second panel shows scanned western blot of SPRY2 and BRAF protein levels in cells 
described in (B), β-actin was used as loading control. (C) Normal Human B cells were 
isolated from healthy donors, cells were stimulated by BCR crosslinking for 24 hours. Cells 
were lysed to prepare lysate for immunoprecipitation. Displayed is a scanned western blot 
of immunoprecipitation with SPRY2 and Syk showing pull down of Raf-1, Syk, BRAF and 
SPRY2. IgG, Pi3K and BTK were used as negative controls.  
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(D) Normal B cells were stimulated as described in (C) cyotospin were prepared using 
these cells. Cells were stained with SPRY2, p-Syk and DAPI fluorescence antibody. 
Displayed are immunofluorescence images showing co-localization of SPRY2 and p-Syk 
in normal B cells and Mec-1 CLL cells. Unstimulated cell, Goat-IgG and Rabbit-IgG were 
used as control.  
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(E) Normal B cells were isolated from spleen of CD19-cre;Spry2(wt) and CD19-
cre;Spry2(tg) mice and were stimulated for 30 mins with anti-IgM antibody. Displayed is 
scanned western blot of p-Syk and Syk and densitometric measurements showing 
normalized decreased levels of p-Syk.  
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(F) Mec-1 CLL cells were overexpressed with Spry2 cDNA and Empty vector co-
expressing GFP, cytospins were prepared of these cells. Slides were stained with p-Syk 
(red) antibody. Displayed are immunofluorescence images and Densitometric 
measurements showing decreased levels of normalized p-Syk in SPRY2 co-expressing 
GFP positive cells.   
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(G) Normal B cells were isolated from healthy donor. Scanned western blot of 4G10 p-
Tyrosine staining of nB-cells after treatment of siRNAs against SPRY2, scr siRNA was 
used as control.  
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FIGURE 8 
 
Spry2 has synergistic effect with Syk and BRAF inhibitor in presence of BRAF V600 
mutation. Mec-1 CLL cells were co-transfected of Empty and Spry2 vectors with BRAF 
V600 mutant and KRAS V12 mutant. (A) Displayed is bar graph of cell viability using MTT 
assay after treating BRAF-V600 mutated cells with BRAF inhibitor with 2.5µM, 5µM and 
10µM (B) Displayed is bar graph of cell viability using MTT assay after treating KRAS V12 
mutated cells with BRAF inhibitor with 2.5µM, 5µM and 10µM. (C) Displayed is bar graph 
using MTT assay after treating BRAF-V600 mutated cells with Syk inhibitor treatment with 
2.5µM, 5µM and 10µM. 
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Table1: Patient’s information for samples used for western blotting and transcriptome 
analysis.  
CLL 
Pateint 
# 
Source Cytogenetics 
IgV 
mutation 
status 
CD38 
positivity 
Monotypic 
B-cells 
CLL 10 PB Normal Mutated Neg 82% 
CLL 23 PB Trizomy 12 Not done Neg 67% 
CLL 22 PB Normal Not done Neg 75% 
CLL 136 PB 13q14 del Not done Neg 74% 
CLL 150 PB 14q Not done Neg 88% 
CLL 3 PB Trizomy 12 Unmutated Pos 93% 
CLL 34 PB 11q23 Not done Pos 74% 
CLL 40 PB 17p del, 13q Unmutated Pos 92% 
CLL 80 PB 
17p del, Trizomy 
12 Unmutated Pos 70% 
CLL 70 PB Trizomy 12, 13q Unmutated Pos 84% 
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Table2: CLL patient’s information used for proliferation and survival.  
LL Pateint # Source Kappa Lamda CD38 positivity 
Monotypic 
B-cells 
CLL 1 PB neg pos neg 81% 
CLL2 PB neg pos neg 85% 
CLL4 PB pos neg pos, dim, partial 82% 
CLL 5 PB neg pos neg 82% 
CLL 8 PB pos neg neg 81% 
CLL 9 BM pos neg neg 67% 
CLL 10 BM pos neg pos, dim, partial 87% 
CLL 12 PB pos neg pos, m 83% 
CLL 13 PB neg pos pos, m 72% 
CLL 20 PB neg pos pos, dim 82% 
CLL 21 PB pos neg pos 93% 
CLL 145 PB neg pos pos,dim 85% 
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Discussion: 
Clinical heterogeneity is a major problem in the management of CLL. The 
molecular basis of clinical heterogeneity is not well understood. The heterogeneous 
clinical outcome in patients appears to be the results of interactions between several 
molecules and cellular pathways. Consequently, in order to treat CLL effectively, a better 
understanding of the molecules and cellular pathways that that contribute to such 
heterogeneous clinical outcome is urgently needed. In the present study we have 
elucidated the molecular basis for BCR-mediated MAPK-Erk signaling where a negative 
regulator SPRY2 plays a major role in regulating the survival and proliferation of CLL cells. 
Moreover, SPRY2 may function as a molecule responsible for maintaining the clinical 
heterogeneity in CLL.  
The BCR and its associated MAPK signaling are constitutively-activated in CLL 
cells and are critical for their survival, migration and proliferation. However, the precise 
molecular mechanisms leading to deregulation of these pathways in CLL cells still remain 
unclear. Our studies here have identified SPRY2 expression as a novel negative regulator 
of BCR-mediated MAPK-Erk signaling pathway in the pathogenesis of CLL. Spry2 
expression is significantly lower specifically in patients with poor prognosis CLL (high 
CD38 expression) which possess features of constitutively-active BCR and MAPK-Erk 
signaling. The expression of other Sprouty family proteins, Spry1, 3 and 4 is particularly 
low across the CLL spectrum without any significant differential expression, thus, 
indicating that SPRY2 is the predominant member of Sprouty protein family of negative 
regulators of signaling whose expression is significantly altered in Good versus Poor 
prognosis CLL.  
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Notably, our findings have also underlined that SPRY2 expression is induced upon 
BCR stimulation and is critical for attenuating BCR-induced MAPK-Erk signaling. 
Moreover, SPRY2 may function as an attenuator of tonic BCR signaling in CLL cells and 
B cells as basal levels of signaling are elevates upon SPRY2 knockdown (Figure 2). While, 
SPRY2 over-expression in CD19-cre;Spry2(tg) mice led to impaired BCR signaling in B 
cells, we did not observe an apparent defect in the overall generation of B cells. Notably 
though, and directly relevant to role of SPRY2 down-regulation in CLL, we observed a 
decrease in the B1 subset of B-cells these mice. These results indicate a potential role for 
SPRY2 in the development of B1 cells and possibly in the initiation of CLL as B1 cells 
have been shown to function as precursors of CLL in mice in multiple model system (62). 
It will be of considerable interest to breed the CD19-cre;Spry2(tg)  mice to established 
models of CLL such as Eµ-Tcl1 or IRF4-/-Vh11 mice to directly study the role of SPRY2 in 
development of CLL (62). Interestingly, SPRY2 levels are down-regulated in CLL cells 
isolated from Eµ-Tcl1 and IRF4-/-Vh11 mouse model (data not shown). Even though no 
other defects in B-cell development are apparent in CD19-cre;Spry2(tg) mice, it will be 
interesting to further study the induction of functional humoral responses in these mice 
given our findings that aberration of SPRY2 expression deregulate BCR signaling.  
Functionally, our studies have shown that SPRY2 mediated regulation of BCR 
signaling is important for survival and proliferation of CLL cells.  Moreover, SPRY2 plays 
a role in controlling the disease aggressiveness as knockdown of SPRY2 in Mec-1 CLL 
cells resulted in more aggressive disease in NSG mice. We show that SPRY2 expression 
in normal B cells and CLL cells leads to a decrease p-Syk levels. Mechanistically, BCR 
signaling in CLL cells constitutes a signaling axis whereby Syk can also function to 
regulate the activation of MAPK-Erk signaling (Figure 8E). Of significant interest in this 
regard, we observed that SPRY2 not only interacts with and antagonizes Raf/Braf 
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activities but that it also interacts and co-localizes with Syk near the plasma membrane to 
disrupt the MAPK-Erk signaling axis (Figure 8E). Therefore, we propose a model in which 
SPRY2 functions to regulate two different nodes of an overlapping signaling axis by 
attenuating Syk as well as Raf/Braf activity (Figure 8E). Importantly, our studies indicate 
that SPRY2 functions as a broad attenuator of BCR signaling via its regulation of Syk 
activity. This is evidenced by a decrease in calcium influx upon BCR stimulation, a process 
mediated by PLCγ2 signaling downstream of Syk activation.  
SPRY2 has been shown to interact with RTKs and the associated adaptor 
molecules through its SH2 domain-binding motifs generated upon its phosphorylation (22). 
Syk is a non-receptor tyrosine kinase harboring multiple SH2 domains. Hence, it is 
tempting to speculate that SPRY2 might interact with Syk using one or more of its SH2 
domain binding motifs. However, the precise domain(s) required for the interaction of 
SPRY2 with Syk is currently unknown. Additionally, how the functional inhibition of Syk is 
brought about by its interaction with Spry2 is an open question. Furthermore, SPRY2 
overexpression in CLL cells induces an anti-survival effect that functions synergistically 
with Syk and BRAF inhibitors. Collectively, these studies highlight the presence of dual 
mechanisms through which SPRY2 regulates BCR-induced MAPK-Erk signaling in CLL 
and B cells as shown in Figure 8E. Thus, our findings provide a strong rationale for 
targeting of these pathways in the treatment of CLL patients, in particular those with MAPK 
pathway associated mutations. A recently study has identified a small subset of CLL 
patients that do not respond to the Btk inhibitor Ibrutinib (63). It will be of interest to 
evaluate the therapeutic potential of a combinatorial Syk and MAPK-Erk inhibition in such 
patients. 
Our study shows that SPRY2 functions as a molecular rheostat important for fine-
tuning the signaling cascades critical for survival and proliferation of CLL. By investigating 
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the mechanism of SPRY2 down-regulation and impact in human CLL cells and mouse 
models, our studies here identify and validate key molecular networks that can be 
therapeutically targeted in the treatment of CLL.  
 
70 
 
Chapter IV 
STAT3 regulates miRNA-21 to target SPRY2 in CLL patients with 
poor prognosis 
Introduction 
Chronic Lymphocytic Leukemia (CLL), is the most prevalent adult leukemia in the 
western world (1-5). Several studies have identified molecular cues leading the 
pathogenesis of CLL (1,2). Despite this, the molecular aberrations leading to CLL onset 
are still under review. Specifically, understanding the role of oncogenes and tumor 
suppressor interplayed during the disease progression might unravels the mechanism 
leading to clinical heterogeneity. Emerging evidences have shown that microRNAs plays 
a critical role during the progression of CLL. MicroRNAs (miRNAs) are small non-coding 
RNAs which are expressed in tissue specific manner (64-66). MiRNAs are involved in 
several cellular processes to maintain the cellular homeostasis. Deregulation of miRNAs 
leads to alteration in expression levels of genes post-transcriptionally, which are involved 
during the development/progression of tumors. In CLL, along with the serving as a 
prognostic markers, miRNAs can function also oncogenes or tumor suppressors. MiRNA-
21 (miR-21) is one such miRNA whose high levels are associated with the poor prognosis 
of CLL patients (41, 42). MiR-21 is located at 17q.23.1 and is highly expressed in CLL 
cells isolated from patients with 17p locus deletion (Del 17p) when compared those from 
CLL patients with wild type 17p locus (42). Notably, patients with chromosomal aberration 
Del 17p results in loss of p53 and has been associated with worst clinical outcomes (67). 
High expression of miR-21 is observed in patients who do not respond to Fludarabine and 
in patients who have shorter overall survival (68, 41, 42).  
Recently, Crespo et al., reported that upon Zap70 expression leads to induction of 
miR-21 expression in B cell receptor (BCR) stimulated primary CLL cells, highlighting the 
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role of BCR signaling in CLL (69, 70). This might be one of the roles of activating MAPK 
and BCR signaling pathways to induce oncomirs like miR21 in CLL cells (70). These lines 
of evidence demonstrate that miR-21 is overexpressed in CLL patients with poor outcome. 
MiR-21 is overexpressed in several other malignancies and targets several tumor 
suppressors like Spry2, Spry1, PDCD4, TPM1 and PTEN (21, 39, 40, 71). However, it is 
uncertain whether Pten is a direct target of miR-21 or its destabilization occurs due to 
down regulation of Spry2 mediated by miR-21 (71). In CLL, miR-21 is often upregulated 
in patients with poor prognosis however, the molecular mechanism leading to its 
deregulation is not fully understood.  
Tumor microenvironment plays a critical role in providing pro-survival signals to 
CLL cells. Several chemokines and cytokines secreted by stromal cells plays important 
role in activating these signaling pathways (72, 73). IL-10 is a classic anti-inflammatory 
cytokines, whose serum levels are often high in patients with CLL (74-76). Secreted IL-10 
binds to IL-10R to activate Jak-STAT3 signaling pathway (75). Constitutive activation of 
signal transducer and activator of transcription (STAT) particularly STAT3, has been 
observed and is frequently associated with CLL disease progression. STAT proteins 
phosphorylates to form dimers to translocates to nucleus and activates transcription. 
Recent studies using STAT3-shRNAs have shown that STAT3 can alter the miRNA 
profiling in CLL cells (77). One of the main target of STAT3 is miR-21 (77). Several groups 
have demonstrated that miR-21 directly targets and downregulates expression of Spry2 
to activate MAPK-Erk signaling in human gliomas and many other malignancies (37, 39, 
40). Together, these studies suggests that targeting of SPRY2 by miR-21 might be one of 
the mechanism of SPRY2 deregulation. Therefore, in this study we have studied the 
SPRY2 as a target of miR-21 in CLL cells. We have also demonstrated that STAT3 binds 
at the promoter of miR-21 to induce its expression in CLL cells.  
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Results:  
Mir-21 targets Spry2 in CLL cells to activate Syk and MAPK-Erk signaling. 
Given the SPRY2 down-regulation in patients with poor prognosis CLL, and a 
cyclic pattern of SPRY2 expression in BCR cross-linked CLL cells (Chapter 4 Figure 2), 
we reasoned that an epigenetic mechanism may deregulate SPRY2 expression in CLL. 
While, spry2 gene is hyper-methylated in DLBCL, Plass et al did not observe any hyper-
methylation of spry2 in patients with CLL (38). Therefore, we sought to identify other 
alternate mechanisms for spry2 down-regulation in poor prognosis CLL patients. 
Interestingly, SPRY2 has been shown to be a direct target of microRNA-21(miR-21) in 
other cell systems (37, 39, 40). Furthermore, mir-21 is an oncomir that has been reported 
to be highly overexpressed in CLL patients with poorer outcome in several studies (41, 
42). Therefore, we overexpressed miR-21 in Mec-1 cells to study whether it can regulate 
Spry2 in CLL cells as shown Figure 1A. Notably, we observed a decrease in SPRY2 
expression in Mec-1 cells expressing high levels of miR-21 compared to those with an 
empty vector control (Figure 1B). Next, we knock down miR-21 levels by using miR-21 
inhibitors and observed significant upregulation of SPRY2 in human CLL cells (Figure 1C).  
Intriguingly, concurrent with SPRY2 down-regulation in miR-21 overexpressing 
Mec-1 cells, we also observed an increase in the levels of p-Syk and p-Erk in the Mec-1 
cells (Figure 2 A-C). In summary, our results here demonstrate that Spry2 is deregulated 
in CLL cells by the expression of miR-21. The results here also, provide a mechanism by 
which miR-21 promotes CLL progression via down-regulation of SPRY2.  
 
 
73 
 
STAT3 expression via IL-10 stimulation induces miR-21 expression in human CLL 
cells.  
 Emerging evidences have shown that miR-21 gets induce upon activation of 
STAT3 signaling pathway (77, 78). To study if STAT3 transcriptionally activate miR-21 in 
CLL cells we next perform chromatin Immunoprecipitation of STAT3. IL-10 mediated 
activation of JAK-STAT pathways is a well-established model used for studying these 
signaling pathways in vivo (75, 76). Therefore, we stimulated CLL cells in vitro with IL-10 
for 12 hours and measured the levels of p-STAT3 and miR-21. Cells cultured without IL-
10 were used as control. We observed that upon IL-10 stimulation there was robust 
induction of p-STAT3 expression when compared with Mec-1 cells alone (Figure 3 A). We 
next stimulated primary CLL cells with IL-10 and measured the levels of miR-21 in these 
CLL cells. After 12 hours incubation we observed a significant 2.7 fold increase in miR-21 
expression (Figure 3 B). We next tested whether the increase in miR-21 levels is via 
STAT3 signaling. To test that after 12 hours post stimulation we performed chromatin 
immunoprecipitation of STAT3. We observed an enhanced amplification at the promoter 
region of miR-21 in CLL cells upon IL-10 stimulation measured by quantitation PCR 
(Figure 3 C). Hence, demonstrating that IL-10 induced STAT3 signaling indeed activate 
miR-21 transcription. 
Inhibition of miR-21 via STAT3 inhibitor stabilizes SPRY2 expression in CLL cells.  
 Our previous studies have demonstrated that the SPRY2 possess an unstable 
biphasic cyclical expression in BCR stimulated CLL cells when compared it with normal B 
cells from healthy donors (Figure 2 Chapter III). First, to study if treatment of CLL cells 
with STAT3 inhibitor decreases the miR-21 expression we next measured the expression 
of miR-21 using q-PCR. We observed a significant reduction at the levels of miR-21 in 
CLL cells treated with STAT3 inhibitor when compared with those from cells only and 
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DMSO treated CLL cells (Figure 4 A). Therefore, we next studied if the inhibition of miR-
21 in CLL cells can stabilize the expression of SPRY2 in CLL cells we used STAT3 
inhibitors. We treated CLL cells shortly with STAT3 inhibitor for 12 hours. After 12 hours 
post incubation these treated CLL cells were washed and then stimulated with anti-IgM 
antibodies. We observed a stable expression of SPRY2 upon BCR stimulation in CLL cells 
treated with STAT3 inhibitor (Figure 4 B). Thus, demonstrating that STAT3 inhibition 
targets miR-21 and stabilizes SPRY2 expression in CLL cells.  
In vitro therapeutic efficacy of STAT3 inhibitor. 
 To test the therapeutic efficacy of STAT3 inhibitor alone and in combination with 
other agents we used primary CLL cells and Mec-1 CLL cells. We first isolated primary 
CLL cells from the peripheral blood of CLL patients. We treated primary CLL cells isolated 
from 11 different patients with STAT3, SYK and BRAF inhibitor at 2.5 µM, 5 µM, 10 µM 
and 15 µM drug concentrations. After 24 and 48 hours post treatments CLL cells viability 
was measured using MTT assay. We observed statistically significant dose dependent 
response with STAT3 inhibitor treated primary CLL cells when compared those with SYK 
and BRAF inhibitors alone treated primary CLL cells (Figure 5 A-B). CLL cells treated with 
SYK and BRAF inhibitors showed significant decrease in cell viability at only higher dose 
of 10 µM. To study if targeting multiple pathways by combinational treatment of BRAF and 
SYK inhibitors with STAT3 inhibitor we used sub IC50 doses of each drug to obtain 2.5 
µM, 5 µM, 10 µM and 15 µM combination drug concentrations (Figure 5 C).  
 As resistance towards Ibrutinib is major challenge in treating patients with CLL (3). 
Therefore, we have developed Ibrutinib resistant Mec-1 CLL cell line, by treating Mec-1 
cells with standard dose of 10 µM for three months. Once the resistant cell line was 
developed, we treated those CLL cells with SYK, Mek-1 and STAT3 inhibitor. Mec-1 cells 
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alone and DMSO treated cells were used as control. We observed a significant reduction 
in cell viability measured by MTT assay of the Ibrutinib resistant CLL cells upon treatment 
with STAT3 inhibitor when compared with SYK and Mek-1 inhibitor at 24, 48 and 72 hours 
as shown in Figure 6 (A-C). Together these studies have demonstrated STAT3 inhibitor 
is more effective in treating CLL patients with Ibrutinib resistance and deregulated MAPK 
signaling.   
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FIGURE1.  
 
MiR-21 targets SPRY2 in human CLL cells  
Mec-1 cells were transfected with pCDNA-mir21 and pcDNA-Empty (A) Graph displaying 
the miR-21 expression measured by quantitative PCR in miR-21 over expressing Mec-1 
CLL cells. (B) Displayed is scanned western blot showing SPRY2 protein levels in miR-21 
overexpressing CLL cells. β-actin was used as loading control. (C) Displayed is a scanned 
western blot of Mec-1 CLL cells after knockdown of miR-21 using miR-21 inhibitor.  
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FIGURE 2 
  
MiR-21 activate BCR mediated MAPK-Erk signaling by targeting SPRY2 in CLL cells. 
(A) Shows protein levels of p-Erk and Erk in miR-21 overexpressing cells. (B) 
Densitometric measurements showing elevated levels of p-Erk in miR-21 overexpressing 
CLL cells. (C) Displayed is scanned western blot showing the protein levels of p-Syk, Syk 
and SPRY2 in miR-21 overexpressing Mec-1 CLL cells.  
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FIGURE 3 
 
 
Regulation of miR-21 and SPRY2 by IL-10 and STAT3 in human CLL cells. 
CLL cells were isolated from the peripheral blood of patients and then incubated with IL-
10 for 12 hours. (A) Displayed is the scanned western blot of pSTAT3 levels in IL-10 
stimulated Mec-1 cells after 12 hours. Beta actin and Mec-1 cells stimulated for 0 hour 
were used as control.  (B) MiRNA was isolated from these cells and quantitative PCR was 
performed using Taqman miR-21 assay. Displayed is quantitative PCR demonstrating the 
induction of miR-21 by IL-10 in primary human CLL cells. CLL only were used as control.   
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Figure 3 (C) Mec-1 cells were stimulated with IL-10 for overnight. Cells were washed and 
DNA was isolated and sonicated. Chromatin immunoprecipitation was perform using 
STAT3 antibody. Displayed is the ChIP analysis demonstrating the binding of STAT3 on 
to miR-21 promoter region by enhancement measured by quantitative PCR.  
 
 
 
 
 
 
 
 
 
 
Mir-21 promoter region  -ve control 
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   FIGURE 4 
 
Down regulation of STAT3 using STAT3 inhibitor in Mec-1 cells decreases miR-21 
and stabilizes SPRY2 expression. 
(A) Mec-1 CLL cells were treated with STAT3 inhibitor for 12 hours. After 12 hours cells 
were washed and miRNA was isolated. Displayed is the quantitative PCR graph 
measuring the level of miR-21 expression using taqman assay. (B) After treating Mec-1 
cells with STAT3 inhibitor for 24 hours, cells were washed and stimulated with anti-IgM 
antibody. Cells were collected at 0, 6, 12, 24 and 48 hours. Displayed is the scanned 
western blot showing stabilization of SPRY2 expression after 24 hours treatment of Mec-
1 CLL cells with STAT3 inhibitor. Mec-1 cell only was used as control.  
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FIGURE 5 
 
Effects of STAT3, Syk and Braf inhibitors alone and in combination on survival of 
CLL cells.  
(A) CLL cells were isolated from the peripheral blood of 11 different patients. CLL cells 
were treated with STAT3, SYK and BRAF inhibitors for (a) 24 hours and (b) 48 hours. 
Displayed is the measurement of the cell viability using MTT assay.  
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FIGURE 5 (B) Treatment of Mec-1 cells with STAT3 inhibitor (5µM) followed by SYK or 
BRAF inhibitor for 24 (a) and (b) 48 hours. 
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FIGURE 6 
A 
 
Therapeutic efficacy of STAT3 inhibitor over SYK and Mek-1 inhibitor in Ibrutinib 
resistant Mec-1 CLL cells.  
Mec-1 CLL cells were treated with 10 µM per milliliter for about 3 months. After 
spontaneous acquired Ibrutinib resistance cells were treated with Syk, STAT3 and Mek-1 
inhibitor for 24 hours (A).  
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(B) Treatment for 48 hours with SYK, STAT3 and Mek-1 inhibitor.   
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(C) Treatment for 72 hours with SYK, STAT3 and Mek-1 inhibitors. Cells viability was 
measured by MTT assay for different doses A- 2.5 µM, B- 5 µM and 10 µM. Mec-1 cells 
only and DMSO treated were used as control. 
 
 
 
 
 
 
 
 
86 
 
Discussion  
Our previous studies identified SPRY2 as one of the molecule which might be 
playing critical role in clinical heterogeneity of patients with CLL. However, the mechanism 
leading to SPRY2 differential expression in between CLL patients with good and poor 
clinical outcome was unclear. In this study we have identified the molecular mechanism 
through which SPRY2 is deregulated in CLL patients. We demonstrated that high levels 
of miR-21 leads to suppression of SPRY2 in CLL cells. Upon knockdown of miR-21 we 
observed the upregulation of SPRY2. We further demonstrated the role of STAT3 
signaling in CLL progression by upregulating miR-21 levels in poor prognosis CLL. Using 
STAT3 inhibitor we identified STAT3 as potential therapeutic target in CLL patients with 
poor prognosis and also in Ibrutinib resistant CLL patients.  
Spry2 is either epigenetically silenced or repressed by miR-21 in several cancers 
including breast, prostrate, lungs, liver and lymphoma (37-40). In human CLL, Chen et al, 
have demonstrated that the promoter region of spry2 was only hypermethylated in a small 
fraction of  the 55 CLL patients that were profiled, signifying alternate mechanisms that 
lead to Spry2 down-regulation in CLL (38). Interestingly, we observed that SPRY2 is a 
direct target of miR-21 in human CLL cells. There are several reports that have correlated 
high miR-21 expression in CLL patients with poorer outcome (41, 42). High MiR-21 
expression has been shown to activate MAPK-Erk signaling in several malignancies by 
suppressing SPRY2 levels (41, 42). However, in this report we have shown the molecular 
mechanism through which miR-21 leads to disease advancement. We observed elevated 
p-Syk and p-Erk levels and low levels of SPRY2 in high miR-21 expressing CLL cells. 
Together, these findings suggest that miR-21 targets SPRY2 to activate Syk-mediated 
BCR and MAPK-Erk signaling in poor prognosis CLL.  
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Persistent activation of STAT3 signaling via IL-10 is critical for oncogenic 
transformation in several cellular system (79). In CLL patients several reports have shown 
the elevated serum levels of IL-10 cytokine (76). However the role of IL-10 signaling in 
CLL was controversial. Our studies revealed the critical molecular mechanism played by 
IL-10 mediated STAT3 signaling in CLL cells. We have shown that upon IL-10 stimulation, 
miR-21 levels were increased via STAT3 transcription factor in human CLL cells. Hence, 
highlighting STAT3 as a potential therapeutic target in CLL cells.  
Using primary CLL cells, Ibrutinib resistant Mec-1 CLL cell line in this study we 
demonstrated the higher therapeutic efficacy of STAT3 inhibitor over SYK, BRAF and 
Mek-1 inhibitors. Upon treating CLL cells with STAT3 inhibitor we observed a significant 
reduction in the levels miR-21 and stable expression of SPRY2 in BCR stimulated CLL 
cells.  Resistance to Ibrutinib acquired by patients is major challenge in treating CLL with 
current therapy (3-6). Elevation of MAPK-signaling and miR-21 is seen in such relapsed 
patients. Intriguingly, we observed more effective therapeutic efficacy of STAT3 inhibitor 
over Mek-1, SYK and BRAF inhibitors. Highlighting the different mechanisms leading to 
activation of these pathways in Ibrutinib resistant CLL cells. These studies warrants further 
in depth analysis of these signaling pathways in CLL patients with acquired resistance to 
Ibrutinib. Together our studies have demonstrated the molecular mechanism through 
which SPRY2 is deregulated in CLL patients and by targeting STAT3 we can inhibit the 
effects of miR-21 in CLL cells.   
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Chapter V 
Conclusion, Caveats and Future Directions:  
Conclusion and Caveats 
Sprouty is significantly reduced in CLL cells isolated from poor prognosis patients 
when compared those from good prognosis.  
Chronic Lymphocytic Leukemia (CLL) is the most prevalent adult leukemia where 
clinical heterogeneity and therapy resistance are the major challenges. Several studies 
have highlighted the critical role played by MAPK signaling in CLL cells proliferation and 
survival (80). About 36% of mutations found in CLL cells isolated from the patients leads 
to constitutive activation of MAPK signaling. Constitutive activation of MAPK signaling is 
one of the driver event for clonal evolution during the CLL disease progression. However, 
the molecular mechanism leading such deregulation is not fully understood. In an attempt 
to unravel these signaling pathways cues we performed transcriptome analysis which 
highlighted that Sprouty (SPRY)2 is significantly downregulated in CLL cells isolated from 
poor prognosis patients when compared with those from good prognosis patients.  
SPRY2 belongs to SPROUTY protein family. These protein plays crucial role in 
providing negative feedback for signaling cascade activated via receptor tyrosine kinase 
(RTK). Interestingly, none of the other SPROUTY proteins (SPRY1, SPRY3 and SPRY4) 
showed significant difference in expression between good and poor prognosis CLL. First, 
to provide in vitro evidence we tested the differential expression level of SPRY2 in CLL 
cells isolated from good and poor prognosis CLL patients. We independently tested the 
expression level of SPRY2 in CLL cells isolated from unmutated-IgVh vs mutated-IgVh 
CLL patients, High CD38 vs Low CD38 CLL patients and Del 17p vs Del 13q CLL patients. 
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We observed significant reduction in SPRY2 expression in CLL cells isolated from all poor 
prognosis patients categorized by different prognostic markers. To further validate this, 
we also measured the protein level by western blotting and mRNA levels by RT-PCR of 
SPRY2 in CLL cells isolated from good and poor prognosis patients. These results 
conclude that SPRY2 is significantly down regulated in CLL cells isolated from poor 
prognosis when compared with those from good prognosis patients.  
SPRY2 is a novel attenuator of BCR signaling.  
Next we studied the role of SPRY2 as a negative regulator in B cell receptor (BCR) 
signaling. To demonstrate this we first stimulated normal B cells isolated from healthy 
donor with anti-IgM antibodies and collected cells at 0, 6, 12, 18, 24 and 48 hours. We 
observed a gradual increase in SPRY2 expression over period of time in normal B cells.  
Whereas, primary CLL cells as well as Mec-1 CLL cells displayed a biphasic cyclical 
expression of SPRY2 suggesting the instability of SPRY2 in CLL cells. Interestingly, we 
observed two bands of SPRY2 upon stimulation. The upper band is due the post-
translational modification of SPRY2 by palmitoylation. Upon addition of palmitoylation 
SPRY2 gets recruited to lipid rafts on the plasma membrane. Using siRNAs mediated 
knockdown of SPRY2 in normal B cells we demonstrated prolonged BCR activation in B 
cells with low levels of SPRY2 shown by the calcium influx assay. Based on results of 
these studies we concluded that SPRY2 is a negative regulator of BCR signaling.  
Caveats:  
The differences are slight in calcium influx but these results are highly repeatable and 
statistically significant. Therefore, more samples must be analyzed.  
SPRY2 negatively regulates the proliferation and survival of CLL cells.  
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To elucidate the role of SPRY2 in CLL cell proliferation and survival, we first used 
CLL cells isolated form good prognosis patients and Mec-1 CLL cells. As good prognosis 
CLL cells possess higher levels of SPRY2 when compared with those from poor prognosis 
patients, we knockdown SPRY2 expression using siRNAs. We observed increase in 
proliferation in BCR stimulated primary CLL cells upon SPRY2 knockdown. To study the 
effect of reconstitution of SPRY2 expression in CLL cells we used CLL cells isolated from 
poor prognosis patients, as they possess very low levels of SPRY2 levels. We expressed 
SPRY2 by transfecting these cells with SPRY2 cDNA followed by a reported GFP tag 
constructs and measured the rate of apoptosis in these cells. Upon reconstitution of 
SPRY2 expression in CLL cells from poor prognosis patients the increase in the rate of 
apoptosis when compared with Empty vector construct transfected cells.  These results 
helped us to conclude that SPRY2 negatively regulates the proliferation and survival of 
human CLL cells.  
To determine if reconstitution of SPRY2 expression in B cells have any effect on 
B cell signaling and B cell development we created a B cell specific Spry2 transgenic 
mouse model (CD19cre-Spry2(tg)). Although, we did not observe any disparity in B cell 
development we did observe that the number of special B cell population, B1 cells was 
significantly reduced. This was particularly interesting as B1 cells were initially presumed 
and lately shown as precursor of CLL cells in mice. The percentage and absolute number 
of B1 cells was specifically reduced in peritoneal cavity of CD19cre-Spry2(tg) when 
compared with those from CD19cre mice. Intriguingly, splenic B cells (B2 cells) showed 
significant reduction in the BCR activation measured by calcium influx in response to BCR 
crosslinking. Next, using this mouse model we have also established the role of SPRY2 
in B cell proliferation. We demonstrated that splenic B2 cells showed no or few cells 
proliferating measured by CSFE labeling in response to anti-IgM and LPS when compared 
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with those from CD19cre mice. Together, these results concluded that SPRY2 negatively 
regulates the survival of B1 cells and attenuates the proliferation of splenic B2 cells in 
response to external stimuli.  
Caveats:  
In our study for survival and proliferation we did not demonstrated the opposite effects of 
SPRY2 knockdown and overexpression. Although we did observe decrease in survival 
upon SPRY2 knockdown in primary CLL-cells but was not statistically significant. The 
subtle changes on survival due to SPRY2 knockdown in primary CLL-cells might have 
been overshadowed by anti-IgM antibody effects on CLL-cells survival in vitro.  In an 
overexpression system with SPRY2-cDNA expressing plasmid, we did not stimulate those 
CLL-cells as BCR stimulation would further increase the levels of SPRY2 in those cells. 
Therefore we did not observe much difference in rate of proliferation. However, further in 
depth analysis are needed with many more primary CLL samples to confirm and conclude 
the opposite effects.  
Low levels of SPRY2 leads to CLL disease advancement.  
To study the role of SPRY2 during CLL disease progression, we modeled the low 
SPRY2 expression seen in human CLL disease in a mouse lymphomagenesis model. For 
this purpose, we established a xenograft model with low SPRY2 expressing Mec-1 CLL 
cells transplanted into NSG mice. We observed mice transplanted with low SPRY2 
expressing Mec-1 CLL developed more rapid and significantly larger tumors when 
compared with those transplanted with control Mec-1 cells. Interestingly, CLL cells isolated 
from these tumors retained low SPRY2 levels and increased levels of p-Erk. Using Tet-on 
inducible system we also observed a dose dependent decrease in p-Erk levels on SPRY2 
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induction. Together, these results concluded that low levels of SPRY2 promotes CLL 
disease progression in xenograft mouse model by activating MAPK-Erk signaling.  
SPRY2 interacts with SYK and RAF-1/BRAF to attenuates BCR mediated MAPK 
signaling.  
Next to study the molecular mechanism by which SPRY2 negatively regulates 
BCR and MAPK signaling in CLL we used stimulated normal B cell as a model to induce 
endogenous SPRY2. As, it was well established that SPRY2 interacts with Ras and/or Raf 
proteins to attenuates MAPK-Erk signaling. However, SPRY2 interaction with these 
proteins varies with cell types. Therefore, we first tested the conservation of these 
networks and showed that SPRY2 interacts with RAF-1 and BRAF in normal B cells upon 
stimulation.   
As, KRAS and BRAF mutations are very commonly found in patients with CLL, we 
next tested if SPRY2 can attenuate MAPK-Erk signaling in the presence of KRAS and 
BRAF mutations in CLL cells. We observed that SPRY2 was still able to attenuate MAPK-
Erk signaling even in the presence of BRAF mutant but not in the presence of KRAS 
mutations. This is was particularly interesting as lately it was shown that upon treating a 
Multiple Myeloma patients with preexisting Monoclonal B lymphocytosis (MBL) with BRAF 
inhibitor led to CLL transformation. The CLL cells were found to activate MAPK-Erk 
signaling via SYK. Also, as SPRY2 possess SH2-domain binding motifs and gets recruited 
in lipid rafts of plasma membrane, we speculated that SPRY2 might be interacting with 
SYK. By performing immunoprecipitation of SPRY2 and SYK in stimulated normal B cells 
we have shown that SPRY2 interacts with SYK upon B cells stimulation. Using 
immunofluorescence we also demonstrated that SPRY2 co-localizes with p-Syk upon 
BCR stimulation.  
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To test if SPRY2 attenuates Syk mediated BCR signaling, we used SPRY2 
expressing Mec-1 cells and splenic B2 cells from CD19cre-Spry2(tg). We observed low 
levels of p-Syk in immunofluorescence of SPRY2 expressing Mec-1 cells and western blot 
of splenic B cells from CD19cre-Spry2(tg) mice when compared with respective controls. 
These results concluded that SPRY2 attenuates BCR and MAPK-Erk signaling through a 
parallel mechanism by interacting with Syk and RAF-1/BRAF in normal B and CLL cells.  
Caveats: 
We demonstrates that SPRY2 interacts with Syk however, it is unclear if SPRY2 and Syk 
interacts directly or they are part of same complex. Therefore, identification of domains 
critical for SPRY2 and SYK interaction is essential to understand the process at the 
molecular level..  
MiRNA-21 targets SPRY2 to activate BCR and MAPK-Erk signaling in CLL cells from 
poor prognosis patients 
 SPRY2 is either epigenetically silenced or targeted with miR-21 in several 
malignancies. It was previously demonstrated that SPRY2 is not epigenetically repressed 
in CLL and miR-21 is highly expressed in CLL cells from patients, we therefore speculated 
that miR-21 targets SPRY2 in CLL. We observed decreased SPRY2 levels in miR-21 
expressing CLL cells and upon knockdown of miR-21, SPRY2 levels were increased in 
these cells. This was particularly interesting as the levels p-Syk and p-Erk increased in 
high miR-21 expressing CLL cells. 
Caveats:  
To establish if SPRY2 is the major target of miR-21 in CLL, rescue experiments are 
needed. Reconstitution of SPRY2 expression in high miR-21 expressing CLL cells will 
demonstrate if SPRY2 is the main target of miR-21 during the pathogenesis of CLL. This 
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will establish if SPRY2 expression can inhibits the phenotype of high miR-21 expressing 
CLL cells.     
IL-10 stimulation activates STAT3 signaling pathways to increases miR-21 levels in 
CLL cells.  
  IL-10 is classical example of inflammatory cytokine whose levels are elevated in 
CLL patients. STAT3 signaling is activated by IL-10 and/or IL-6 stimulation, however the 
role of IL-10 signaling in CLL is still unclear. As it is very well established that STAT3 
activation affects the levels of miR-21 in CLL. We showed that upon IL-10 stimulation 
STAT3 binds at the promoter region of miR-21 to increase the levels of miR-21. We also 
demonstrated that upon treating CLL cells with STAT3 inhibitor, the levels of miR-21 goes 
down and SPRY2 expression is stabilized. Also, STAT3 is a better therapeutic target in 
CLL cells with mutations associated with MAPK signaling pathways and in Ibrutinib 
refractory CLL. Together, we conclude that STAT3 signaling is one of the molecular 
mechanism for the high miR-21 expression in CLL cells.  
Caveats: 
The role of IL-10 on CLL cells survival and proliferation is not known. Therefore, IL-10 
stimulated CLL cells must be evaluated for their survival and proliferation.  
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Figure 1: Proposed model  
 
We conclude that SPRY2 is a target of miR21 in CLL cells from poor 
prognosis patients. MiR21 targets SPRY2 to activate Syk mediated BCR and 
MAPK signaling in CLL patients. IL-10 induces miR-21 expression in CLL 
cells via activation of STAT3 signaling pathway. Also, STAT3 can be used as 
therapeutic target for poor prognosis CLL patients with high miR21 
expression. 
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Future Directions:  
1. To identify the role of SPRY2 in CLL disease initiation. Although, we 
demonstrated that constitutive expression of SPRY2 in vivo decreases the number 
of B1 cells the role of SPRY2 in CLL initiation is not get understood. To study this 
CD19cre-Spry2(tg) can be crossed  with a well-established CLL mouse model. As 
SPRY2 levels are low in Vh11IRF4 deficient mouse model therefore, reconstitution 
of SPRY2 expression in these mice will provide a demonstration of SPRY2 role in 
CLL initiation. Expected Results: We expect to see delay in the development of 
CLL in these mice.   
2. To identify the domains critical for SPRY2 and SYK interaction. SPRY2 
possess SH2-domain binding motifs, it will be interesting to study if SPRY2 binds 
with SYK at SH-2 domains. To test this we will use SYK and SPRY2 mutants 
lacking these critical domains and perform immunoprecipitation of SPRY2 and 
SYK. Using this approach we will demonstrate the domains important for Syk and 
SPRY2 interaction. Expected Results: We expect that SPRY2 interacts with SH-
2 domains of Syk. 
3. To identify the molecular mechanism for biphasic expression of SPRY2 in 
CLL cells. We have shown that SPRY2 possess a biphasic cyclical expression 
upon BCR stimulation in CLL cells. Therefore, to elucidate the molecular 
mechanism we will evaluate the expression of miR-21 and SPRY2 together in BCR 
stimulated CLL cells. We will treat CLL cells with Mir-21 inhibitor and study if the 
expression of SPRY2 expression is stabilized. Expected Results: We expect that 
the levels of miR-21 inversely correlates with SPRY2 levels in stimulated CLL cells.  
4. To elucidate the role of miR-21 in CLL initiation and disease progression. We 
have shown that miR-21 targets SPRY2 to activate BCR mediated MAPK-erk 
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signaling. As miR-21 is specifically highly expressed and deregulated in relapsed 
and refractory CLL patients. Therefore, it will be interesting to study the role of 
miR-21 in CLL disease progression by crossing miR-21 knockout mouse model 
with Eµ-TCL1 mouse model. We will also perform gene expression profiling of CLL 
cells isolated from patients with high miR-21 expression and low mir-21 
expression. This will allow us to study the targets of miR-21 important in CLL 
disease progression. Expected Results: We expect SPRY2 is the major target of 
miR-21 in CLL disease progression.  
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Appendix 1 
Stromal Tumor Microenvironment in Chronic Lymphocytic Leukemia: 
Regulation of Leukemic Progression 
Shukla A, Chaturvedi NK, Ahrens AK, Cutucache CE, Mittal AK, et al. (2013) 
Stromal Tumor Microenvironment in Chronic Lymphocytic Leukemia: Regulation 
of Leukemic Progression. J Leuk (Los Angel) 1:113. doi: 10.4172/2329-
6917.1000113 
Abstract 
Chronic Lymphocytic Leukemia (CLL), the most prevalent adult leukemia in western 
countries, which is highly heterogeneous with a very variable clinical outcome. Emerging 
evidence indicates that the stromal tumor microenvironment (STME) and stromal 
associated genes (SAG) play important roles in the pathogenesis and progression of 
CLL. However, the precise mechanisms by which STME and SAG are involved in this 
processes remain unknown. In an attempt to explore the role of STME in this process, 
we examined the expression levels of stromal associated genes using gene expression 
profiling (GEP) of CLL cells from lymph nodes (LN) (n=15), bone marrow (BM) (n=18), 
and peripheral blood (PB) (n=20). Interestingly, LUM, MMP9, MYLK, ITGA9, CAV1, 
CAV2, FBN1, PARVA, CALD1, ITGB5 and EHD2 were found to be overexpressed while 
ITGB2, DLC1 and ITGA6 were under expressed in LN-CLL compared to BM-CLL and 
PB-CLL. This is suggestive of a role for LN-mediated TME in CLL cell 
survival/progression. Among these genes, expression of MYLK, CAV1 and CAV2 
correlated with clinical outcome as determined by time to first treatment. Together, our 
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studies show that members of the stromal signature, particularly in the CLL cells from 
lymph nodes, regulate CLL cell survival and proliferation and thus leukemic progression. 
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Introduction:  
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous, incurable B 
cell malignancy affecting elderly population in the western world. Emerging evidence 
suggest that CLL cells depend on complex communications with their microenvironment 
for survival. Due to an overt dependence of CLL cells on these interactions, their survival 
is greatly reduced when cultured in vitro by themselves. We and others [1,2] have shown 
that the tumor microenvironment (TME) in lymph nodes (LN) provide pro-
survival/proliferation signals to CLL cells and induces host immune suppression [3]. 
Furthermore, prolonged survival of CLL cells in the proliferation centers in bone marrow 
(BM) and in LNs is mediated by several stromal micro-environmental (STME) cues; 
however, the precise nature of these interactions remains ambiguous. LN 
microenvironment is comprised of stromal and other cells along with the associated 
extra cellular matrix. Extra cellular matrix is comprised of proteoglycans, integrins, 
hyaluronic acid and reticular network. On the other hand, stromal and other cells in the 
lymph nodes represented by lymphatic endothelial cells, mesenchymal cells, T cells, 
follicular dendritic cells and monocytes-derived nurselike cells have been shown to 
enhance CLL cell survival [4]. The STME helps them to escape from therapy resulting in 
increased relapse rate in CLL patients [4]. Once the tumor cells colonize in LNs, they 
shape their microenvironment to support their own survival and growth. This partly 
involves the activation of immune tolerance genes in CLL cells [3]. Recently Garcia-
Munoz et al. have suggested that immunoglobulin gene mutated CLL cells in the LN, 
acquire self-reactivity for auto antigens while being tolerized with receptor editing [5]. As 
a consequence, the normal function and proliferation of nonmalignant B cells in the TME 
are also affected [5]. Lenz et al. have eloquently demonstrated that survival of diffuse 
large B cell lymphoma following treatment is influenced by the differences in immune 
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cells, fibrosis and angiogenesis in the TME [6]. This conclusion was based on the 
analyses of stromal gene signatures in large B cell lymphomas. 
Orimo et al. have reported that stromal fibroblasts present in invasive human 
breast cancer promote tumor growth and angiogenesis through elevated SDF/CXCL12 
secretion [7]. Together, these reports advocate the importance of complex interactions 
between CLL and other tumor cells with their microenvironment for increased 
proliferation leading to disease progression. In B cells, such interactions involve 
cytoskeletal changes possibly mediated by stromal microenvironment leading to 
enhanced B cell activation by BCR clustering [8,9]. Similar mechanisms may impose 
altered cytoskeletal changes in CLL cells leading to better survival and proliferation. 
Therefore, identification of molecular network involved in modification of LN 
microenvironment by CLL cells will lead to a better understanding of the disease. In an 
attempt to understand the molecular basis of stromal associated regulation of CLL 
progression and its prognostic implication we performed a gene expression profiling 
(GEP) of CLL cells from PB, BM and LN. We also performed transcriptome analysis of 
PB-CLL cells from patients with good versus poor prognosis to identify stromal gene 
signatures associated with disease aggressiveness. We identified two genes, MYLK and 
CAV2, whose transcript and protein expression is upregulated in patients with poor 
prognosis than good prognosis and significantly associated with patient’s outcome. 
CLL patient information:  
Using an Institutional Review Board approved-protocol and informed consent, 
CLL samples were obtained from patients. PB (n=20), BM (n=18) and LN (n=15) 
samples from 53 CLL samples were collected from 37 different patients. In addition, to 
validate the results, additional peripheral blood CLL samples from 20 patients and 
another 15 patients with good prognosis (n=7) and poor prognosis (n=8) patient 
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peripheral blood samples were also used. In this study, we included CLL patients who 
are untreated and who did not receive any treatment for six months prior to sample 
collection. For control, B cells from age matched normal donors were obtained.  
The clinical information on these 72 patient are provided in Table 1 a-c. 
CLL cells isolation and characterization:  
All CLL samples for this study were obtained using an UNMC Institutional Review 
Board approved protocol. CLL cells were isolated from PB and BM using density 
gradient centrifugation with lymphocyte separation medium, LymphoPrep, followed by 
negative selection using magnetic bead separation method as needed [10, 11]. Frozen 
LN samples were obtained from the UNMC tissue bank. CLL cells were localized on 
frozen LN samples using immunohistochemistry by staining CD19 and CD5 positive 
cells. Fifteen to twenty sections of 8-10 micron thickness were made at 4oC and fixed 
immediately by ice-cold acetone and stained with cresyl violet (LCM Staining Kit, 
Ambion, TX, USA) for 30 seconds. These cells were micro dissected for RNA isolation 
[2]. For CLL cells isolated from PB and BM, the purity was tested by flow cytometry 
using the combination of CD3-FITC, CD19-PE, CD5-PE, CD38-PE and CD19-FITC (BD 
Biosciences, San Jose, CA, USA). 
Clinical Characterization of CLL patient:  
Patients with high CD38 positive, bulky lymphadenopathy, chromosome 11q 
deletion, 17p deletion and trisomy 12, unmutated IgVH and shorter time to first treatment 
were considered as a poor prognosis patient, whereas patients with only 13q deletion or 
normal karyotype, mutated IgVH and longer time to treatment were considered as a 
good prognosis patient [11, 12].  
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Microarray analysis:  
RNA from CLL cells was extracted using TRIzolTM (Invitrogen, Grand Island, NY, 
USA) as per the manufacturer’s instruction. Gene expression profiling was performed 
using a DNA microarray chip (MWG Biotech, Germany, Human 30K oligo set B) 
consisting of a 50-mer oligonucleotide representing 10,000 different genes. cDNAs were 
obtained from RNA using Stratagene manufacturer’s instructions. The hybridized slides 
were scanned and images were collected by an Axon 4000B scanner (Axon 
Instruments, Grand Terrace, CA, USA). Differentially expressed stromal signature genes 
were identified using significance analyses of microarray (SAM). 
Transcriptome analysis:  
RNA from peripheral blood B cells of seven good prognosis CLL patients and 
eight poor prognosis CLL patients was isolated as mentioned above. mRNA levels of 
stromal related genes with significant p value were compared between good and poor 
prognosis patients. The RNA sequencing was done at the UNMC Next Generation 
Sequencing Core facility using Illumina HiSeq 2000 sequence analyzer. RNA sequence 
alignment was done by TopHat alignment software; this was followed by Picard 
processing for removal of duplicates. To identify differential gene expression levels 
among the good versus poor prognosis, Cuffdiff method was used. To determine the 
relative fold change the values were normalized with GAPDH. Clinical information of 
these 15 patients is provided in Table 1 (d). 
Clinical correlation of the gene expression levels:  
The Kaplan Meier analysis log-rank test was used to analyze clinical correlation 
of gene expression levels or clinical parameters with time to first treatment. Time to 
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treatment is the interval in months between diagnosis and initiation of the first treatment 
in months among the CLL patients. In some cases the CLL cells used in the study were 
classified based on cytogenetic chromosomal abnormality, where CLL cells 13q deletion 
and normal karyotype were considered as good prognosis and CLL cells with 11qdel, 
trisomy 12 and 17p deletion as poor prognosis group. Also CD38 low (less than 30% 
positive) or immunoglobulin gene mutation and CD38 high (more than 30%) or 
unmutated immunoglobulin gene were also grouped as good and poor prognosis, 
respectively. 
Western blotting:  
The expression of MYLK, EHD2, DLC1 and CAV1 in B cells from a normal 
healthy donor, five good prognosis CLL patients and five poor prognosis CLL patients 
were determined using western blot analyses. 50 µg of protein was loaded on 10% SDS-
PAGE gel, which was separated by electrophoresis, and blotted on PVDF membrane. In 
brief, the membrane was incubated with primary antibodies of MYLK and DLC1 (Santa 
Cruz Biotechnologies, Dallas, TX, USA), CAV1 (Abcam, Cambridge, MA, USA), EHD2 
(homemade antibody was kindly provided by Dr. Hamid Band, UNMC) and β-actin 
(Sigma Aldrich, St. Louis, MO, USA). This was followed by incubation of membranes 
with appropriate secondary antibodies and blot was developed using Enhanced 
Chemiluminescence, Pierce ECL Western Blotting Substrate (Thermo Scientific, 
Waltham, MA, USA).  
Statistical Analysis:  
For the identification of differentially expressed genes, a significant analysis of 
microarray (SAM) was used. To identify the tissue specific gene signatures, analysis 
was performed using random variance t-test with p-value of 0.01 and false discovery 
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rate (FDR) of 0.08. The most of analyses were performed at p<0.05 and FDR<0.25, 
unless specified otherwise. The Kaplan-Meier method using log-rank test was used to 
study the association of gene expression or clinical parameter with the clinical outcome 
as done previously [13]. 
Results 
Supervised cluster analyses of differential expression of stromal signature I and II 
associated genes in primary CLL cells:  
Figure 1 shows a supervised cluster analyses of the differential expression of 
stromal signature I & II genes in CLL cells isolated from peripheral blood (PB), bone 
marrow (BM) and lymph nodes (LN) from patients in comparison to each other and with 
normal B cells from healthy donors (nB). In the case of stromal signature I, 119 genes 
were analyzed. There were in total 47 genes that are differentially expressed. Among 
these 47 genes, 30 genes were overexpressed and 17 genes were under expressed 
compared to each other. Among the 30 genes overexpressed, based on the transcript 
levels, we divided them into the categories of high (11 genes), medium (8 genes) and 
low (11 genes) expressing genes based on the fold change in their expression 
compared to reference as shown in Table 1. In this Stromal I gene signature, these 
differentially expressed genes are associated with extracellular matrix, cytoskeleton 
maintenance, cell migration, and biosynthesis of collagen. We have recently shown that 
the CLL cells in the LNs induce immune tolerance against themselves to facilitate their 
uninhibited growth [2]. Interestingly,  many of the genes including SERPINH1, 
SERPINF1, FBN1, APOE, PTGDS, LUM, CALD1 and MYLK were significantly 
overexpressed in CLL cells in the LNs compared to BM, PB and nB. 
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In the case of stromal II genes, there were a total of 35 genes; of these, 22 genes were 
differentially expressed genes. Among these 22 genes, 14 genes were overexpressed 
and 8 genes were under expressed in CLL cells compared to normal B cells. Among the 
overexpressed genes, 7 genes had high expression levels and 7 genes had medium 
expression levels and there were no genes in which expression was relatively low 
compared to other genes in the category. Stromal signature II shows the mRNA level of 
genes which are associated with intracellular compartment: EHD2, SDF1, PTPRB, 
CAV2 and CAV1 [14] were overexpressed, whereas DLC1, which is a known tumor 
suppressor [15], was under expressed in both stromal signatures I & II.  
Validation of differential expression using transcript levels of selected stromal 
genes in CLL cells from PB, BM and LN:  
We confirmed the differential expression of selected genes by evaluating the 
mRNA levels of each gene. In these analyses, we either compared the gene expression 
to the expression levels in normal B cells, and/or compared to normal B cells as well as 
to CLL cells from PB, BM and LNs. Figure 2 shows the results of these analyses. There 
was an increased expression of MYLK and decreased expression of DLC1, 
CSPG2/VCAN and ITGB2 in CLL B cells (Figure 2A, B, C and D). Further comparison of 
these three and additional genes with CLL cells from PB, BM and LN and normal B cells 
showed there was a significantly increased expression (p <0.05) of MYLK, EHD2, CAV2 
in CLL cells from the LNs compared other cells in these analyses group (Figure 2E, F 
and G). In contrast, the expression of DLC-1 and CSPG2/VCAN were significantly 
decreased (p< 0.05) in the CLL cells from the lymph nodes compared to rest of the cells 
in this analyses group (Figure 2H and I).  
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Validation of differential expression of selected genes at protein levels using 
western blotting:  
As further validation for higher expression of MYLK, CAV1 and EHD2 and lower 
expression of DLC1 seen in the transcript analyses, we performed comparison of protein 
expression on the basis of disease progression. The evaluation of protein levels of these 
genes was done using PB CLL cells from five patients with good prognosis and CLL 
cells from five poor prognosis and normal donor B cells. Figure 3 shows the results of 
these analyses. There was an increased expression of MYLK1, EHD2 and CAV2 in all 
five CLL patients with poor prognosis compared to CLL cells from five good prognosis 
patients, whereas the expression levels of DLC1 was significantly higher in good 
prognosis patients compared to CLL cells from poor prognosis patients. In these 
analyses, β-Actin was used as housekeeping gene control. Together these analyses 
confirmed the differential expression these selected genes. 
Clinical significance of stromal genes:  
Next, in order to understand the clinical significance of the differentially 
expressed genes, we compared the expression levels of expression of stromal signature 
I associated genes whose transcript analysis were statistically significant, namely 
CEBPA, MYLK, APOE, RAB32, PTGDS and WNT2B and levels of expression of stromal 
signature II associated genes, namely DLC1, CAV2, EHD2, SDF1, RBP4 and ROBO1, 
with the time to first treatment in patients. Figure 4 shows the results of these analyses 
using Kaplan Meier analyses with log-rank test. We have previously shown that high 
expression CAV1 correlated with clinical outcomes, also knockdown of CAV1 impaired 
CLL cells to migrate and formation of immune synapse [2]. Among the 12 genes we 
evaluated, higher expression of MYLK and CAV2 (Figure 4 D and G) significantly 
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correlated with poor clinical outcome. Recently Yamasaki T et al, showed higher 
expression of CAV2 promotes cell proliferation, migration and invasion in renal cell 
carcinoma [16]. DLC1 is a known tumor suppressor and the western blot analysis 
confirmed the down regulation at the protein level which made it interesting to see the 
clinical outcome. However, although not statistically significant, higher expression of 
WNT2B and EHD2 and lower expression of DLC1 showed clinical correlation (Figure 4 
A, E and K). The rest of genes did not show clinical correlation with time to first 
treatment in patients.   
Gene expression levels determined by RNA sequencing:  
In order to identify additional genes which are associated with extracellular matrix 
we did comparative analysis of differential gene expression in Good Prognosis CLL and 
Poor prognosis CLL using RNA transcriptome analysis. The mRNA level of genes 
encoding for cell surface proteoglycan and glycoprotein those also associated with 
stromal signature I & II as mentioned above like VCAN and CD93 were 50 and 20 fold 
up-regulated respectively; inflammatory related cytokines associated genes like IL8, 
CXCL1 and CXCL3 were 40, 77 and 111 fold up-regulated respectively in good 
prognosis; and SPP1 and SERPINB2 were 955 and 1271 fold higher than poor 
prognosis respectively.  Among these  differentially expressed genes identified in our 
transcriptome analyses,  expression levels of proteins of selected extracellular matrix 
genes were evaluated using Western blot analyses. There was a significantly increased 
protein level of VCAN, SPP1 and SERPINB2 in CLL cells from good prognosis 
compared to CLL cells from poor prognosis patients (Figure 5).  Thus these results 
validated the differential expression of certain extracellular matrix associated genes as 
identified in transcriptome analyses.  
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Figures and Tables: 
 
 
Differential expression of stromal signature I and II associated genes in primary 
CLL cells: GEP showing differential expression of Stromal Signature I & II in cells 
isolated from peripheral blood (PB), bone marrow (BM) and lymph nodes (LN) from CLL 
patients in comparison with normal B cells from healthy donors (nB). Stromal Signature I 
and II showing the differential gene expression in extra cellular matrix compartment and 
cellular components of CLL patients and healthy donors.  mRNA level of some 
cytoskeleton related genes like MYLK, APOE and PTGDS from stroma I, EHD2, CAV2 
and CAV1 from stroma II were high, whereas tumor suppressor genes like DLC1 was 
down regulated in both stroma I & II.  
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Expression levels of stromal genes in CLL cells from PB, BM and LN: Comparison 
of mRNA expression of (A) myosin light kinase (MYLK), (B) versican (VCAN), (C) 
deleted in liver cancer (DLC1), (D) Integrin, Beta 2 (ITGB2) in PB isolated B cells from 8 
healthy donors and 20 CLL patients. mRNA expression comparison of (E) myosin light 
kinase (MYLK), (F) EH domain containing 2 (EHD2), (G) caveolin 2 (CAV2), (H) deleted 
in liver cancer (DLC1) and (I) versican (VCAN) in B cells from PB of 8 healthy donors 
and B cells from PB, BM and LN samples from 37 CLL patients samples. Student t-
TEST was applied to determine the statistically significance among the normal healthy 
donors and CLL patients. “*” determine p value of ≤ 0.05. The relative expression was 
normalized by GAPDH.  
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Figure 3:  
 
 
 
 
 
Analysis for protein expression: Expression of selected proteins in normal B and CLL 
cells from PB of 5 good prognosis and 5 poor prognosis patients using western blotting.   
MYLK 
DLC-1 
EHD2 
CAV-1 
β-Actin 
5 Poor         5 Good nB 
CLL samples 
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Clinical significance of stromal genes:  Clinical correlation of expression levels of 
stromal signature I associated genes (CEBPA, MYLK, APOE, RAB32, PTGDS and 
WNT2B) and stromal signature II associated genes (DLC1, CAV2, EHD2, SDF1, RBP4 
and ROBO1) in CLL patients using Kaplan Meier analyses with log-rank test. Among 
these genes, expression of MYLK, WNT2B, DLC1, EHD2 and CAV2 in stromal signature 
I and II correlated with clinical outcome as determined by time to treatment. 
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Figure 5:  
 
Validation of differentially expressed extracellular matrix associated genes in 
good and poor prognosis CLL samples using analyses for protein expression: 
Expression of selected extracellular matrix associated proteins in CLL cells from PB of 4 
good prognosis and 4 poor prognosis patients using western blotting method. 
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Table 1: (a) Peripheral Blood CLL patient samples information: 
Patients 
ID Age Gender 
Time to 
treatment  
Fluorescence in-situ 
Hybridization Bulky disease CD 38% 
IgVH Mutation 
status 
PB12 69 M 1 NA No lymphadenopathy 45% NA 
PB16 51 M 1 Trisomy 12; 17p-; 13q14- Bulky adenopathy 89% NA 
PB22 66 F Never NORMAL No lymphadenopathy 12% NA 
PB37 53 M NA NORMAL No lymphadenopathy 4% NA 
PB82 79 M 4 Trisomy 12 , 13q14 del BALA 92% Unmutated 
PB89 39 M 10 Trisomy 12 (23% - 56%) 
Mild 
lymphadenopathy 3% NA 
PB90 66 F Never 13q14 del No lymphadenopathy 20% NA 
PB96 85 F 1 NORMAL 
Mild 
lymphadenopathy 9% NA 
PB97 54 F 2 NORMAL Lymphadenopathy 51% NA 
PB106 65 M Never 13q null No lymphadenopathy 27% NA 
PB107 58 M 2 
11q22.3/ATM (96%); 
13q14 deletion (96.5%) 
LN (axilla, 
supraclavicular, 
mediastinal ) 1.50% NA 
PB109 44 M 0.25 
11q22.3/ATM (96%), 
13q14 (12%), (14q32 del, 
77.5%) LN (neck and axilla) NA NA 
PB117 80 M 48 
13q14 (87.5% - 96%) IgH 
(12.5%) BALA (axillary) 32.45% NA 
PB121 47 M Never 13q14 (72%) No lymphadenopathy 7% NA 
PB124 53 F Never Blood14q32 (35.5%) No lymphadenopathy 11% NA 
PB134 57 M 82 13q nullosomy No lymphadenopathy 23% NA 
PB141 71 M Never 13q14 (38.5%) No lymphadenopathy 24% NA 
PB143 69 F Never 
13q14 (53.5%), cyto-N; 
13q14 (83%) No lymphadenopathy 12% NA 
PB146 76 F 17 
11q23 (84.5%), 13q14 
(15.5%) No lymphadenopathy 43% NA 
PB149 41 M 6 
17p- (11%), 13q- (33%), 
14q- (12%) LN (neck) 8% NA 
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(b)Lymph Nodes CLL patient samples information: 
Patients 
ID Age Gender 
Time to 
treatment  
Fluorescence in-situ 
Hybridization Bulky disease CD 38% 
IgVH 
Mutation 
status 
LN11 59 M 1 
TRISOMY 12 (47%); 14q32 (25%), 
then 12% n 13% after that 17p del 
Yes, diffuse abdominal, axilla, 
groin, neck LN 80% Unmutated 
LN34A 74 M 2 11q23 from 13qdel BALA 63% NA 
LN34B 74 M 2 11q23 from 13qdel BALA 63% NA 
LN40A 49 M 1 
13q14 (68.5%),both11.5%,null 
13.5%, then 17p13 in LN; BALA 92% Unmutated 
LN40B 49 M 1 
13q14 (68.5%),both11.5%,null 
13.5%, then 17p13 in LN; BALA 92% Unmutated 
LN59 62 F 108 NA Lymphadenopathy   NA 
LN64 72 F 48 17p13 *                             Lymphadenopathy   NA 
LN66A 61 F 11 
11q22.3/ATM (78%), 13q14 
(89%), 17p13.1 (3 copies in 
46.3%)            BALA 84% Unmutated 
LN66B 61 F 11 
11q22.3/ATM (78%), 13q14 
(89%), 17p13.1 (3 copies in 
46.3%)            BALA 84% Unmutated 
LN67 42 M 1 11q23, 13q14            BALA 21% Unmutated 
LN82 79 M 4 Trisomy 12 , 13q14 del BALA 92% Unmutated 
LN83A 29 M 22 
11q23 deletion (92%), 14q32 
(64.5%) BALA 98% Unmutated 
LN83B 29 M 23 
11q23 deletion (92%), 14q32 
(64.5%) BALA 98% Unmutated 
LN93 50 M 1 14q- BALA 52% NA 
LN149 41 M 6 
17p- (11%), 13q- (33%), 14q- 
(12%) LN (neck) 8% NA 
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(c)Bone marrow CLL patient samples information: 
Patients 
ID Age Gender 
Time to 
treatment  Karyotype Bulky disease CD 38% 
IgVH Mutation 
status 
BM12 69 M 1 NA No lymphadenopathy 45% NA 
BM16 51 M 1 Trisomy 12; 17p-; 13q14- Bulky adenopathy 89% NA 
BM32 65 F NA 13q14 Lymphadenopathy 34% NA 
BM34 74 M 2 11q23 from 13qdel Lymphadenopathy 63% NA 
BM37 53 M NA NORMAL No lymphadenopathy 4% NA 
BM67 42 M 1 11q23, 13q14            BALA 21% Unmutated 
BM74 55 M Never 13q13 deletion No lymphadenopathy 5% Mutated 
BM83 29 M 22 11q23 deletion (92%), 14q32 (64.5%) BALA 98% Unmutated 
BM89 39 M 10 Trisomy 12 (23% - 56%) Mild lymphadenopathy 3% NA 
BM106 65 M Never 13q null No lymphadenopathy 27% NA 
BM117 80 M 48 13q14 (87.5% - 96%) IgH (12.5%) BALA (axillary) 32.45% NA 
BM120 65 M 3 14q- LN (neck) 34% NA 
BM122 50 M 17 various del, 17p del, 20q-, 7p- No lymphadenopathy 33.50% NA 
BM124 53 F Never blood- normal in BM-14q32 (35.5%) No lymphadenopathy 11% NA 
BM152 60 M Never 13q- (48%) No lymphadenopathy NA NA 
BM163 70 M Never 13q null (24%), 13q- (46%) No lymphadenopathy 23% NA 
BM166 52 M Never NORMAL LN(axillary) 28% NA 
BM168 56 F Never 13q null (11%), 13q del (66%) mild LA NA NA 
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(d)Patients Clinical information used for Transcriptome:  
Patients 
ID 
Age Gender 
Time to 
treatment  
Fluorescence in-situ 
Hybridization Bulky disease CD 38% 
IgVH Mutation 
status 
CLL 3 61 F 98 TRISOMY 12 (65.5%) No lymphadenopathy 83% Unmutated 
CLL 11 59 M 1 
TRISOMY 12 (47%); 14q32 (25%), then 
12% n 13% after that 17p del 
Yes, diffuse abdominal, 
axilla, groin, neck LN 80% Unmutated 
CLL 29 55 F 69 
11q23- (91%);13q14 mono 
(95.5%),13q14(60%); 14q32 (65.5%) BALA 17% Unmutated 
CLL 30 55 F 12 Trisomy 12 (70.5%) Lymphadenopathy 55% Unmutated 
CLL 34 74 M 2 11q23 from 13qdel BALA 63% NA 
CLL 40 49 M 1 
13q14 (68.5%),both11.5%,null 13.5%, 
then 17p13 in LN; BALA 92% Unmutated 
CLL 79 62 M 15 
11q22.3 (78%), 13q14 (53.5%), 
null13q14 (34%) No lymphadenopathy 23% Unmutated 
CLL 82 79 M 4 Trisomy 12 , 13q14 del BALA 92% Unmutated 
CLL10 49 F Never Normal No lymphadenopathy 6% Mutated 
CLL 13 83 M 1 Normal No lymphadenopathy NA NA 
CLL 19 56 F Never 13q14- No lymphadenopathy NA NA 
CLL 75 34 M 96 Normal No lymphadenopathy 3% Mutated 
CLL 100 70 F Never 13q14 No lymphadenopathy 18% NA 
CLL 108 63 M Never 13q14 and 14q32 rearrangement No lymphadenopathy 9% NA 
CLL 164 64 F 12 Normal No lymphadenopathy NA NA 
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Table 2:  Expression of the stromal signature 1 and 2 genes in LN-CLL 
compared to PB-CLL, BM-CLL and normal B-cells in gene microarray analysis. 
The Overexpressed genes were categorized into high (>2 fold), medium (>1.5 
fold) and low (~1.5 fold) higher expressed genes compared to PB-, BM-CLL and 
normal B-cells. 
 
Signature Overexpressed Genes Underexpressed 
Genes  High Medium Low 
 
 
 
 
 
 
Stromal 1 
 
Apoe 
Clu 
Lum 
Mmp9 
Mylk 
Robo1 
Wnt2b 
Cxcl14 
Pcolce 
Serpinf1 
Cox7a1 
 
Aebp1 
Col4a4 
Cyr61 
Fbn1 
Lama4 
Parva 
Ptgds 
Evc 
 
Adamdec1 
Cald1 
Chn1 
Ctgf 
Ctsk 
Dzip1 
Edg2 
Itgb5 
Ppa2b 
Rarres1 
Sparc 
 
Adra2a 
Angpl2 
Cebpa 
Cspg2 
Cyp27a1 
Dlc1 
Edil3 
Gja1 
Islr 
Maff 
 
 
Pkd2 
Ptprf 
Rab32 
Rtn1 
Ceecam 
Fap 
Itgb2 
 
 
 
Stromal  2 
 
Itga9 
Saa1 
Cav1 
Cav2 
Fabp4 
Ced6 
Ehd2 
 
Col5a3 
Lamb1 
Prrg1 
Sh3d5 
Pa2ga 
Sparcl1 
Aqp1 
  
Sema4c 
Dlc1 
Sdf-1 
Procr 
Apm1 
Kdr 
Itga6 
Rbp4 
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Table 3: Comparative analysis of differential gene expression of genes encoding 
extra cellular matrix components in Good Prognosis CLL and Poor prognosis 
CLL using RNA transcriptome analysis. The result shows relative fold change in 
the mRNA expression of particular genes states the upregulated genes in good 
prognosis. 
Gene 
Symbol 
Gene Name 
Upregulated in Good 
Prognosis  (Relative 
Fold Change)  
q value 
VCAN Versican Core Protein isoform 3 precursor 50 0.00453231 
SPP1 Osteopontin isoform a precursor 955 0.0463267 
IL8 Interleukin-8 precursor 40 0.00027589 
CD93 
Complement component C1q receptor 
precursor 20 0.0081508 
CXCL1 Growth-regulated alpha protein precursor 77 0.00492674 
CXCL3 C-X-C motif chemokine 3 111 0.00090857 
SERPINB2 
Plasminogen activator inhibitor 2 
precursor 1271 1.2298E-09 
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Discussion 
In this report, we have studied the nature of expression of stromal signature 
genes in CLL cells from PB, BM and LNs.  CLL cells, particularly in the patient’s body, 
proliferate and survive for a long time; however, they do not survive long once they are 
removed from the body, suggesting the role of in vivo microenvironment. Evidence from 
literature indicates that CLL cell’s inability to survive in vitro is due to lack of complex 
interactions between CLL cells and the surrounding microenvironment. We and others 
[1, 2] have shown that the tumor microenvironment (TME) in the LN provides pro-
survival/proliferation signals to CLL cells leading to the formation of proliferation centers 
(PCs) with varied sizes from small to extensively large. It is previously demonstrated that 
CLL cells at the tissue sites such as LNs induce host immune suppression via differential 
expression of tolerogenic genes reported earlier in T cell malignancy [17]. Based on our 
previous studies, we believe that the CLL lymph node induced host immunosuppression 
significantly contributes to the leukemic progression in CLL patients [2]. However, the 
precise mechanism of the process and particularly the role played by stromal genes in 
CLL in the tissue microenvironment is not known. Therefore, the current study was 
undertaken. 
Lenz et al [5] have reported that in the case of diffuse large B cell lymphoma, 
stromal signature predicted the clinical outcome. In the present study, differentially 
expressed genes from both stromal I and II signatures were involved in the poor 
prognosis CLL with LN involvement. For example in the case of one of the 
overexpressed genes MYLK, a member of the stromal signature I, higher expression of 
this gene was correlated with poor prognosis. Similarly, CAV1 [2] and CAV2 members of 
the stromal II signature are overexpressed in CLL cells from LN and correlated with poor 
clinical outcome in patients. Furthermore, in the current study, the higher expression of 
131 
 
CAV2 is correlated with poor prognosis. In addition, Myosin Light Chain Kinases 
(MLCKs) are a group of proteins found in smooth muscle and phosphorylates myosin II 
regulatory light chains at Ser19, allowing myosin cross bridges to bind to actin filaments 
and initiate contraction [18, 19]. Interestingly, we have recently reported [2] that over 
expression of CAV1 in CLL cells in the lymph nodes might be involved in inhibiting 
immune synapse formation via regulating the actin polymerization. This leads us to 
speculate that MYLK might be involved in the CAV1 mediated inhibition of immune 
synapse formation of CLL cells in the LNs. Further, in-depth analyses are needed to 
confirm the role for MYLK in the CAV1 mediated immunosuppression specifically 
inhibition of immune synapse formation. In this regard, we also see the over expression 
of CAV2, associated with  poor prognosis in CLL, might also be involved in interacting 
directly with G-protein alpha subunits and thus functionally regulate their activity through 
phosphorylation of Ser-36 to modulate mitosis in CLL cells. This might be through being 
a positive regulator of cellular mitogenesis of the MAPK signaling pathway. 
Our transcriptome analyses of extracellular matrix associated genes revealed an 
over expression of VCAN, SPP1 and SERPINB2 in CLL cells from good prognosis 
patients. Although we do not know the significance of the elevated expression of these 
genes in CLL biology it is possible that these genes interact with CAV1 and CAV2 in 
regulating immune response towards CLL, this need to be addressed to understand the 
role of these overexpression genes. 
 In summary, differential gene expression of stromal signature I and II highlighted 
cytoskeleton associated genes like MYLK, CAV1, CAV2 and EHD2 which were 
significantly upregulated in CLL cells from patient’s LNs. Expression levels of stromal 
associated genes MYLK, DLC1, WNT2B, EHD2 and CAV2 correlated with clinical 
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outcome. Thus, our results suggest that STME provides survival signals to CLL cells and 
facilitates the resistance to therapy which might be leading to leukemic progression.  
In addition our transcriptome analyses showed several genes associated with 
extracellular matrix significantly upregulated in good prognosis. These results lay the 
foundation for in-depth analyses of these genes to elucidate the functional significance 
at the mechanistic levels of the differential expression of the relevant genes. 
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Appendix II 
Absence of caveolin-1 leads to delayed development of chronic 
lymphocytic leukemia in Em-TCL1 mouse model 
Shukla A, Cutucache CE, Sutton GL, Pitner MA, Rai K, Rai S, Opavsky R, Swanson 
PC, Joshi SS. Exp Hematol. 2016 Jan;44(1):30-7.e1. doi: 
10.1016/j.exphem.2015.09.005. Epub 2015 Oct 3. 
Abstract 
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United 
States. The tissue microenvironment, specifically the lymph nodes, influences the 
biological and clinical behavior of CLL cells. Gene expression profiling of CLL cells from 
peripheral blood, bone marrow, and lymph nodes revealed Cav-1 as one of the genes 
that might be involved in the pathogenesis of CLL. We have previously reported that the 
knockdown of Cav-1 in primary CLL cells exhibits a significant decrease in cell migration 
and immune synapse formation. However, the precise role of Cav-1 in CLL initiation and 
progression in vivo is not known. Therefore, we decreased the expression of Cav-1 in 
vivo by breeding Em-TCL1 with cav-1 knockout mice. We observed a significant 
decrease in the number of CLL cells and rate of proliferation of CLL cells in spleen, liver, 
and bone marrow from Em-TCL1- Cav1/+ and Em-TCL1-Cav1/ mice as compared with 
Em-TCL1 mice. In addition, there was a significant increase in survival of Em-TCL1-
Cav1/+ and Em-TCL1-Cav1/ compared with Em-TCL1 mice. Mechanistically, we 
observed a decrease in MAPK-Erk signaling measured by p-Erk levels in Em-TCL1-
Cav1/+ mice when compared with Em-TCL1- Cavwt/wt. Together these results indicate 
that decreased Cav-1 in Em-TCL1 mice significantly delays the onset of CLL and 
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decreases leukemic progression by inhibiting MAPK-Erk signaling, suggesting a role for 
Cav-1 in the proliferation and progression of CLL.  
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INTRODUCTION 
Chronic Lymphocytic Leukemia (CLL) is a clinically heterogeneous, currently 
incurable and the most common adult leukemia in the Western world (1,2). Despite 
advancement in treatment strategies, the overall survival of CLL patients is still about 7 
years. Therefore, in order to develop effective therapy we need to understand the 
molecular basis of clinical heterogeneity. Emerging evidence has convincingly 
demonstrated that the tumor microenvironment (TME) plays an important role on clinical 
and biological behavior of CLL (3-8). We have earlier reported that CLL cells in the 
lymph node (LN) TME have aggressive clinical outcome and express B cell associated 
proliferation and survival genes including a tolerogenic gene signature (host immune 
tolerance associated genes) (7). Among the tolerogenic gene signature, Caveolin-1 
(Cav-1) is the most highly overexpressed gene in CLL cells from LN compared to 
peripheral blood (PB) and bone marrow (BM) (3,6).  
Earlier we have shown that Cav-1 is indeed associated with the regulation of 
human CLL cell behavior in vitro (7). Besides being a scaffolding molecule involved in 
vesicular transport, Cav-1 is also shown to be a multifunctional protein with tumor 
associated functions such as cellular transformation, tumor growth and progression, 
multi-drug resistance, angiogenesis, cell migration and metastasis. Cav-1 also functions 
as an oncogene or tumor suppressor gene depending on the tissue microenvironment 
(9,10). In a clinical study Burgermeister et al have shown that Cav-1 upregulation is 
associated with tumor progression and metastasis in different human cancers (11). We 
have shown earlier that Cav-1 is also involved in the regulation of immunological 
synapse formation of CLL cells (7). In addition, it has been shown that Cav-1 regulates 
actin polymerization; these studies indicate a role for Cav-1 in the CLL leukemogenesis 
and/or progression (12). 
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Therefore, in this study we crossed cav-1 null mice with the Eµ-TCL1 transgenic 
mice, a murine model for aggressive CLL. The offspring mice were examined for the 
onset and dissemination of CLL cells in the bone marrow, spleen, lymph node, liver and 
peripheral blood using antibodies to CD5/CD19/B220 molecules and flow cytometry. Our 
results have shown that there was a significant decrease in CLL in the Eµ-TCL1-Cav1-
/+ and Eµ-TCL1-Cav1-/- mice as demonstrated by flow cytometry and a significant 
decrease in rate of proliferation of CLL cells in spleen as demonstrated by the Ki-67 
immunohistochemical analyses.  Together these results demonstrate that cav-1 is 
involved in the leukemogenesis and progression of CLL. 
METHODS 
CLL cell isolation from mouse:  
Spleen, bone marrow and lymph nodes were isolated from animals and minced 
into single cell suspension. Splenocytes and bone marrow cells were incubated in red 
blood cell (RBC) lysis buffer for 5 minutes at room temperature. After incubation, cells 
were washed twice with phosphate buffered saline (PBS) to remove lysed RBCs. 
Following RBC lysis, mouse CLL cells were isolated using negative selection with a 
mouse B cell isolation kit by Miltenyei Biotech. Purified cells were processed for either 
RNA isolation or flow cytometeric analysis see supplementary figure 1.  
Reverse transcription-PCR:  
Total RNA was extracted and purified from CLL cells using the TRIzolTM method 
(Invitrogen, Carlsbad, CA). Template cDNA was synthesized using SuperScript III 
(Invitrogen, Carlsbad, CA). To determine the expression levels of selected tolerogenic 
genes in CLL cells  from mice, we performed real-time PCR using a cocktail of 10l 
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Power SYBR green master mix (Applied Biosystems, Foster City, CA), a final 
concentration of 10pm of primer, 2l of cDNA, and brought to a final volume of 20l per 
reaction with water.  We assessed the integrity of isolated RNA by mass spectrometry 
and 0.8% agarose gel electrophoresis. Results were compared to a housekeeping gene, 
Gapdh. List of primers of all the genes is presented in Table 1 in supplementary data.  
Generation of Eµ-TCL1-Cav1-/- and Eµ-TCL1-Cav1-/+ mice:  
E-TCL1 mice were obtained from Dr. Carlo Croce (Ohio State University, 
Columbus, OH) and were bred with C57BL/6J (Jackson Laboratories, Bar Harbor, 
Maine) to establish a colony. Mice were housed at Creighton University Medical Center 
or the University of Nebraska Medical Center, Omaha, NE. Mice had access to food and 
water ad libitum in microisolater cages. E-TCL1 mice and wild-type (WT) age-matched 
controls were sacrificed once transgenic mice appeared to be moribund.  Additional mice 
were euthanized at 6, 12, 24, 36, and 36+ weeks of age to perform time-course analyses 
of disease progression. Cav-1 knock out (STOCK Cavtm1Mls/J) mouse model was 
purchased from Jackson Laboratory and bred with Eµ-TCL1 and C57BL/6 to establish a 
colony. Genotyping was performed to obtain Eµ-TCL1-Cav1-/- and Eµ-TCL1-Cav1-/+.  
Immunophenotyping:  
Cells from Eµ-TCL1, Eµ-TCL1-Cav1-/- and Eµ-TCL1-Cav1-/+ mice from lymph 
nodes, spleen and bone marrow. Cell suspensions from spleen, BM, and LNs were 
prepared from E-TCL1 and littermate controls. Cells were blocked with serum 
containing medium (PBS with 5% fetal bovine serum). Splenocytes were flow sorted for 
CD5+B220+CD19+ cells. Both CD5+CD19+ and CD5-CD19+ cells were collected for 
downstream analyses. Cells from spleen, bone marrow and lymph nodes were stained 
with the following antibodies: CD5 (eBioscience, San Diego, CA), B220 (BD Bioscience, 
140 
 
San Diego, CA) and CD19 (BD Bioscience). All data generated by flow cytometry were 
analyzed using FlowJo Flow Cytometry Analysis Software version 9.2 (Ashland, OR). 
Immunohistochemistry and H&E staining:  
Liver, spleen, and lymph nodes were collected from each mouse, fixed in 10% 
buffered formalin for 72 hours, and embedded the next day.  Five-micron sections of 
each tissue were stained with H&E to determine gross histology.  Additionally, serial 
sections were used for immunohistochemistry of these tissues.  Briefly, paraffin-
embedded samples were incubated in two changes of xylene for 5 minutes each. Next, 
slides were transferred to 100% alcohol for 2 chances, 3 minutes each, followed by 
incubation in 90%, 80%, and 70% alcohol for 3 minutes each. Endogenous peroxidase 
activity was blocked by incubating sections in 3% hydrogen peroxide, then in methanol 
for 10 minutes and then was rinsed for two changes at 5 minutes each in PBS. Antigen 
retrieval was performed by boiling the sections in 10mM sodium citrate buffer, pH 6.0, 
and then slides were allowed to cool for 10-20 minutes. Slides were washed with PBS 
for two changes at 5 minutes each. Tissues were then incubated with blocking buffer 
(10% fetal bovine serum in PBS) for 1 hour in a humidified chamber. Appropriate primary 
antibody (Ki-67 1:200 (BD biosciences, San Jose, CA), Cav-1 1:100 (Abcam, 
Cambridge, MA), p-Erk 1:200 (Cell signaling technologies, Danvers, MA), CD5 1:150, 
and B220 1:100) was added and samples were incubated overnight in a humidified 
chamber at 4C. Slides were then washed two times with PBS and secondary antibody 
(goat anti-mouse HRP conjugated, Santa Cruz Biologicals, Santa Cruz, CA) was added 
and tissues were incubated at room temperature for 4 hours.  Tissues were then washed 
twice more and DAB was added for developing. 
Survival Analyses:  
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The survival of these offspring mice was monitored and compared using the 
Kaplan–Meier method. One event represents death of one mouse; mice were sacrificed 
upon getting sick. Survival analyzed in the log rank test using sigma plot software (13).   
 
Statistical Analyses:  
To determine the significance of our results, statistical analysis was performed 
using student t-test with the p>0.05 was considered significant unless specified.  For the 
in vivo studies, we analyzed at least three mice of each unless specified. There was 
difficulty in obtaining Eµ-TCL1-Cav1-/- therefore, we have used Eµ-TCL1-Cav1-/+ more in 
our analysis.  
 
RESULTS: 
The goal of this study was to determine the role of cav-1 in CLL disease 
progression in vivo by crossing cav1-/- mice with Eµ-TCL1 transgenic mice. These 
studies yielded the following results.  
Cav-1 expression is significantly increased in mice with CLL.  
We have previously shown the importance of Cav-1 in immune synapse 
formation, survival and migration in human CLL in vitro (7). However, the role of Cav-1 in 
tumor microenvironment was not precisely studied. Therefore, to understand the role of 
tolerogenic signature in tumor microenvironment of mouse CLL, we selected few 
significantly deregulated genes in human CLL naming Ido1, Tgfbr1, II22, Cav1, II2Ra, 
Zwint, Tgfb, IL10ra and Foxp3 from the gene expression profiling we completed 
previously. We next looked for their expression in primary CLL cells from lymph nodes of 
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CLL bearing Eµ-TCL1 mouse model. By performing RT-PCR we found all of the genes 
except Tgfb and Tgfbr1 were also significantly overexpressed in CLL cells from Eµ-TCL1 
mice (Figure-1). These results demonstrated that the Eµ-TCL1 mouse model possesses 
a tolerogenic signature similar to human CLL. Therefore, we selected this model to study 
the role of cav-1 in CLL disease progression.  
The expression level of cav-1 increases with disease progression in Eµ-TCL1-
Cav1wt/wt mouse model.  
CLL is a heterogeneous disease whose clinical outcome varies. In our previous 
studies we have shown that Cav-1 is significantly overexpressed in CLL cells from poor 
prognosis CLL patients. The expression of Cav-1 was specifically high in CLL cells from 
lymph node proliferation centers. Therefore, we wanted to study whether the expression 
of Cav-1 and two associated genes varies along with the disease progression. To 
examine that we isolated CLL cells from LNs of Eµ-TCL1 mice at the age of 12, 24 and 
36 weeks. For control we used C-57B6 wild type mice. Interestingly, the expression of 
cav-1 increased 4 fold with the disease progression whereas gene like Prkcb1 shows 
initial decreased and then increase expression with the disease progression (Figure-2). 
On the other hand, Ptpn6 shows a decrease in expression along with the disease 
progression. This establishes the importance of cav-1 in CLL disease progression in Eµ-
TCL1 mice. Therefore, the increase in cav-1 expression supported our previous finding 
showing the importance of cav-1 in human CLL.   
Delayed and Decrease in CLL development in Eµ-TCL1-Cav1-/- and Eµ-TCL1-Cav1-/+ 
mice.  
It has already been reported by our group that cav-1 knock down induces 
spontaneous apoptosis in primary CLL cells (7). Based on this, we wanted to study the 
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effect of loss of cav-1 in CLL disease progression. The Eµ-TCL1 mouse model starts 
showing expansion of CLL cells at the age of 24 weeks. As shown previously by Nganga 
et al., CLL cells in Eµ-TCL1 mouse model are CD19 positive and B220(low)CD5 positive 
as shown in Figure 3 (A) (14). For control we used aged matched C57B6 mice. In Eµ-
TCL1 mice, splenomegaly starts due to CLL cells infiltration and proliferation around at 
the age of 24 weeks as measured by spleen size, weight and confirmed by flow 
cytometry (15). To study if the loss of cav-1 in Eµ-TCL1 will delay or decrease the CLL 
development/progression in Eµ-TCL1 mice we used a cav-1 germ line knockout mouse 
model. We used the germ line knock out model considering cav-1 is a part of the 
cytoskeleton as well as stromal signature which might be providing a tumor 
microenvironment to CLL cells (8). To address this, we crossed cav-1 knockout mice 
from Jackson’s laboratory with Eµ-TCL1-Cav1wt/wt mice kindly provided by Dr. Rene 
Opavsky at UNMC. Resulting offspring were Eµ-TCL1-Cav1-/- and Eµ-TCL1-Cav1-/+ 
mice. Decrease in Cav-1 expression was measured by IHC of spleen sections from Eµ-
TCL1-Cav1-/+ and Eµ-TCL1-Cav1wt/wt animals from 9 month of age Figure 4 A.   
In Eµ-TCL1-Cav1wt/wt we first observed the expansion of B220 and CD5 positive 
CLL cells in spleen at 24 weeks of age and at the age of 36 weeks, these mice have fully 
developed CLL as shown in Figure 3 A&B. At the age of 36 weeks (9 months), Eµ-TCL1-
Cav1wt/wt gets aggressive CLL with about 75-90% CLL cells in the spleen Figure 3 C. We 
therefore analyzed all the mice at the age of 36 weeks (age of 9 months). We next 
examined Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1-/- for frequency of CLL cells in the spleen 
and bone marrow. In Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1-/-, there was significant 
decrease in B220/CD5 positive B cells in Bone Marrow and Spleen see Figure-4 (A). In 
spleen there were 12% B220+CD5+ cells in Eµ-TCL1-Cav1-/- whereas in Eµ-TCL1-Cav1-
/+ there were 23% CLL cells. In bone marrow we observed 6% and 11% CLL cells in Eµ-
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TCL1-Cav1-/- and Eµ-TCL1-Cav1-/+ respectively. Also the spleen size was significantly 
reduced as shown in Figure-4 B. With regard to spleen size and weight, in the case of 
Eµ-TCL1-Cav1 -/+ mice, we observed varying size and weight ranging from small, 
medium and larger medium with corresponding frequency of CLL cells as shown in  
Figure 4 B. To this end we analyzed five Eµ-TCL1, ten Eµ-TCL1-Cav1 -/+ and one Eµ-
TCL1-Cav1-/-. There was significant reduction in the average number of CLL cells in 
spleen of Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1-/- as shown in Figure 4 C. Hence, we 
concluded that Cav-1 is important for CLL disease progression. In addition we monitored 
the survival of the offspring mice Eµ-TCL1-Cav1wt/wt and Eµ-TCL1-Cav1-/+. There was a 
significant increase in the survival of Eµ-TCL1-Cav1-/+ mice compared to Eµ-TCL1-
Cav1wt/wt mice (p= 0.002) as shown in Figure 4D.    
Decreased CLL cells infiltration and proliferation in cav-1 deleted Eµ-TCL1 mice.  
We have previously shown that Cav-1 is important for CLL cells migration in vitro. 
Therefore, to study its effect in vivo we analyzed the infiltration of CLL cells in the 
spleen, lymph nodes, liver, kidney and lungs in these mice. In Eµ-TCL1-Cav1wt/wt mice, 
the CLL cell infiltration is in all the organs, specifically liver and spleen therefore, 
hepatosplenomagly was observed. In contrast, the size of spleen and liver and infiltration 
of CLL cells was significantly reduced in Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1-/- mice as 
shown in Figure-5 A. We also performed immunohistochemistry of continuous spleen 
sections with B220 and CD5 to ensure presence of CLL cells in these organs Figure-5 B. 
As discussed earlier, Cav-1 plays an important role in tumor progression therefore we 
next wanted to study its effect on CLL cells proliferation in splenic CLL cells of these 
mice. We performed immunohistochemistry of spleen section with Ki-67 stain to 
measure proliferation of CLL cells in Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1wt/wt animals 
from 9 month of age. We observed a significant reduction in proliferating CLL cells in 
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spleen of Eµ-TCL1-Cav1-/+ when compared with spleen of Eµ-TCL1-Cav1wt/wt as shown 
in Figure-5 C. Cav-1 is known to regulate MAPK-Erk signaling by increasing p-Erk levels 
in several cancers including prostate cancer (16). Therefore, to elucidate the molecular 
mechanism leading to decrease in CLL cell proliferation we examined the levels of p-Erk 
in these tissues. We observed significant reduction in the p-Erk levels in spleen of Eµ-
TCL1-Cav1-/+ when compared with spleen of Eµ-TCL1-Cav1wt/wt as shown in Figure-5 D. 
Therefore, we concluded that deletion of cav-1 in Eµ-TCL1 lead to a decrease in CLL 
cells proliferation and infiltration with delayed onset of leukemia.  
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
FIGURES AND TABLES 
Figure 1:   
 
Cav-1 expression is significantly increased in mice with CLL.  
Expression of selected genes of the Tolerogenic Signature was measured in CLL 
cells from lymph nodes of Eµ-TCL1 mice using quantitative real time PCR. The 
expression levels are expressed as fold change in relative gene expression of Ido-1, 
Tgfbr1, IL22, Cav-1, IL2Ra, Zwint, Tgfb, IL10ra and Foxp3 in CLL cells from Eµ-TCL1 
and in comparison to normal B cells from B57BL-6 mice. GAPDH, a house keeping gene 
was used for normalizing the expression. N=3 mice, 36 weeks of age; *p≤0.01, #p≤0.05.  
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Figure 2:  
The expression level of Cav-1 increases with leukemic progression in Eµ-TCL1-
Cav1wt/wt mouse model.  
Expression of Cav-1, Prkcb1 and Ptpn6 was measured in CLL cells from Eµ-
TCL1 mice during CLL progression using quantitative real time PCR.  CLL cells were 
isolated from LNs of Eµ-TCL1 and C57BL-6 mice at 12, 24 and 36 weeks of age. 
Expression levels were measured and expressed as fold change in relative expression 
comparison to normal B cells. GAPDH, a house keeping gene was used for normalizing 
the expression.  
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Figure 3:  
 
Development of CLL in Eµ-TCL1 mice:   
To determine the development of CLL, the frequencies of B220low CD19 CD5 positive 
CLL cells in spleen and bone marrow of Eµ-TCL1 mice at 12 and 36 weeks of age in 
comparison with C57BL-6 mice was measured using flow cytometry (Figure 3A). Figure 
3 B shows the gain in spleen weight n=3 in each group. Spleen weight of wild type mice 
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36+ weeks was not done.  Figure 3 C shows CD19+CD5+ CLL cells in spleen and bone 
marrow cells from the 36+ week old Eµ-TCL1 mice. 
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Figure 4:  
 
Significantly reduced CLL progression in Eµ-TCL1-Cav1-/+ mice.  
Eµ-TCL1-Cav1wt/wt, Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1-/- mice were euthanized 
at 9 month of age. Figure 4 A shows the decreased expression of Cav1 in Eµ-TCL1-
Cav1-/+  and no expression in Cav1-/- mice when compared with Eµ-TCL1-Cav1-/+ mice. 
CLL cells from spleen and bone marrow were stained with B220 (APC) and CD5 (PE). 
Figure 4 B shows B220 and CD5 positive cells in spleen and bone marrow in Eµ-TCL1-
Cav1-/+ and Eµ-TCL1-Cav1-/- comparing with Eµ-TCL1-Cav1wt/wt. Figure 4 C shows the 
decrease in size of spleen from Eµ-TCL1-Cav1-/+, Eµ-TCL1-Cav1-/- and Eµ-TCL1-
Cav1wt/wt 9 months of age mice. Figure 4 D shows the average percentage of CLL cells 
in spleen of Eµ-TCL1-Cav1wt/wt (n=3), Eµ-TCL1-Cav1-/+ (n=10) and Eµ-TCL1-Cav1-/- 
(n=1). The difference between Eµ-TCL1-Cav1wt/wt and Eµ-TCL1-Cav1-/+ is statistically 
significant with p=0.01.  Figure 4 E shows a significant increase in survival time of the 
Eµ-TCL1-Cav1-/+ compared to Eµ-TCL1-Cav1 wt/wt mice as determined by Kaplan Meier 
curve method and analyzed by the log rank test. 
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Figure 5:  
 
Decreased CLL cells infiltration and proliferation in Cav-1 deleted Eµ-TCL1 mice. 
A. Sections of organs of Eµ-TCL1-Cav1wt/wt, Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1-/- 
animals from 9 month of age. Mice were euthanized at 9 months of age and a part of 
spleen, and liver were fixed in formaldehyde and later sectioned for staining with 
hematoxylin and eosin. Photographs were taken at 2.5X, 10X and 20X. Tumor-bearing 
animals had visually larger lymphoid organs with diffuse lymphocyte infiltration. 
Additionally, aggressive disease was ensured as we could detect lymphocytes near 
vessels in the mouse liver and the livers of transgenic animals enlarged significantly.  
Figure 5 B shows immunohistochemistry of Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1wt/wt 
mice spleen sections showing less CLL cells. Spleen sections of Eµ-TCL1-Cav1-/+ and 
Eµ-TCL1-Cav1wt/wt animals from 9 month of age. Mice were euthanized at 9 months of 
age and a part of spleen were fixed in formaldehyde and later sectioned for staining with 
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CD5 and B220 antibodies. Photographs were taken at 20X and 40X. A reduced number 
of B220 and CD5 positive cells were observed in Eµ-TCL1-Cav1-/+ when compared with 
Eµ-TCL1-Cav1wt/wt mice. Figure 5 C Shows immunohistochemistry staining of Ki-67 stain 
to measure the proliferating cells in Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1wt/wt animals 
from 9 month of age. 
 
 
Figure 5 D shows the immunohistochemistry staining of p-Erk in CLL cells in spleen of 
Eµ-TCL1-Cav1-/+ and Eµ-TCL1-Cav1wt/wt animals from 9 month of age. 
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SUPPLEMENTAL DATA 
Supplemental Figure 1: Showing the percentage of the CLL cells in lymph nodes after 
purification used for analyses in Figure 1 and Figure 2.  
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Supplemental Table I. The following table describes the primers used for analysis of 
tolerogenic genes for this study.     
Primer/ 
Gene Name 
Sequence 5’ to 3’ (F/R) Expected 
Product 
AKT CCAACACCTTCATCATCCGC/CACCTCCATCTC
TTCAGCCC 
200bp 
BCL2 TTGTTGTTGTTCAAACGGG/GGCTGGGCACAT
TTACTGTT 
140bp 
CAV1 TGAGATTCAGTGCATCAGCC/AACTTGAAATTG
GCACCAGG 
191bp 
CEBPA TGGACAAGAACAGCAACGAG/TTGTCACTGGT
CAGCTCCAG 
130bp 
c-FOS TGGCGTTGTGAAGACCATGACAG/GCTGCAGC
CATCTTATTCCTTTCC 
129bp 
c-MYC AAAATTGAACACGCTCGGAC/ACACTGGTGGT
CCTACTGCC 
177bp 
CTLA4 TGGTACTGGCCAGCAGCCGA/ACTGGAGGTG
CCCGTGCAGA 
191bp 
FGFR1ISO8 TATGCTTGCGTAACCAGCAG/GTCCAATATGG
AGCTACGGG 
167bp 
FOXP3 CAGCTGCTCGCACAGATTAC/TGCAGCTTTGA 138bp 
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GGTTGTTTG 
HSP90 AGACACAGGCATTGGCATGA/AAAGCCAACAC
CAAACTGCCCA 
139bp 
IGFBP6 GGGCAGGAGTGCGGGGTCTA/CATCCTGTGG
GCGGGCAGTG 
193bp 
IL10Rα ACGCTCATGGGACAGAGCTGC/TCCATACCTC
AGGAGCGCCAC 
132bp 
IL22 TGTCTGCAATGGCCGCCCTG/GTGGGAGCTGA
TGGGCGCAG 
125bp 
PDK1 AGTGACCGAGGAGGTGGCGT/AAACCAGCCA
GAGGCACTGCG 
116bp 
STAT1 TGATGGCCCTAAAGGAACTG/CAGAGCCCACT
ATCCGAGAC 
143bp 
ZWINT GGTTTCTGCAGAGGGTAAGC/ACAGCCTTGAA
GGACACACC 
150bp 
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Discussion: 
Cav-1 regulates a variety of cellular processes in normal and pathologic conditions such 
as cancer. In this report, we have demonstrated that decreased expression of cav-1 
results in significantly delayed onset, increased survival and reduced the number of CLL 
cells in tissues such as spleen, bone marrow and liver. Like in other cancers, over 
expression of Cav-1 is associated with leukemia progression in CLL as we have seen in 
Figure 2 that a parallel increase in cav-1 expression along with CLL progresses in Eµ-
TCL1 murine model for CLL (17-19).  In this regard our study opens up avenues to 
explore and elucidate the precise role(s) played by cav-1 in the pathogenesis of CLL. 
Multifunctional Cav-1, a well-studied molecule for its scaffolding function, is also involved 
in the regulation of initiation and progression of cancers including CLL. Some of these 
Cav-1 functions are mediated via its binding partners such as Prkcb1 and Ptpn6 as there 
is an inverse relationship between the expression of cav-1 and Ptpn6/Prkcb1 expression 
in CLL (Figure 2).  
Our data represents the first report on the definitive role for cav-1 in the leukemogenesis 
and progression of CLL using appropriate murine models. Interestingly, decreased Cav-
1 expression in these mice produced different results in Eµ-TCL1-Cav1-/- versus Eµ-
TCL1-Cav1-/+ mice. Varying degree of CLL infiltrations created varying spleen 
size/weight, which was observed in the Eµ-TCL1-Cav1-/+ mice. The reason for this we do 
not know at this time. However, additional studies at the molecular levels will be required 
to address this question.  
We have earlier reported that the knocking down of Cav-1 using siRNA in primary CLL 
cells resulted in the significant decrease in immune synapse formation by the CLL cells 
(7). At this time, we have not observed any gross alteration in the morphology of the 
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lymphoid tissues in these offspring resulted from crossing Eµ-TCL1 and cav1-/- mice.  
Although alterations in the immune functions in the cav-1-/- mice have been reported (20-
23), in this study we did not perform analyses of immune function in these mice.  Cav-1 
has been shown to regulate the cell migration; possibly via regulating the actin 
polymerization (24-28).  The decreased infiltration of CLL in the offspring might be due to 
altered migration of CLL cells or it could be due to general decrease in leukemic 
progression. Mechanistically, we observed that decrease in cav-1 leads to decrease in 
p-Erk expression in CLL cells from spleen. As MAPK-Erk signaling is critical for CLL cell 
proliferation and migration, we reasoned MAPK-Erk signaling to be the major target of 
cav-1 in these mice. Due to decrease in Erk signaling we observed reduction in CLL cell 
proliferation and delayed in disease progression in these mice leading to better survival. 
However, the precise mechanism through which cav-1 regulates p-Erk levels still 
remains unclear.  
In this study we have not evaluated the normal B cell development particularly the B1 
cells, the precursors of CLL in mouse. However,  Bai et al  (2014) have reported that  
frequencies of B cells was significantly decreased in cav-1 deficient mice as determined 
by the hematopoietic reconstitution method using  cav-1 deficient bone marrow 
transplantation into their wild type counterpart  animals (29). In this regard in our study 
we have observed a decrease in CLL cell frequency and delayed onset of leukemia in 
Eµ-TCL1-Cav1 +/- mice. This means pan decrease in B cells might not be the main 
reason for the reduced severity and delayed onset of CLL in the offspring mice. 
In CLL cells from lymph nodes, the Cav-1 expression is significantly high compared to 
CLL cells from the bone marrow and peripheral blood (6, 7). We also have shown that 
CLL cells in the lymph nodes have more aggressive phenotype compared to CLL cells 
from the other tissue site. The molecular basis of lymph node associated 
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aggressiveness of CLL and increased expression of Cav-1 in lymph node CLL cells is 
not known at this time (6).  
In order to understand the precise role of Cav-1 in the pathogenesis of CLL, our results 
warrant further studies exploring the additional proteins/molecules that interact with Cav-
1 in regulating the CLL biology. In this regard, it would be interesting to study the activity 
of the Pkrcb1 or Pten in these mice offspring. 
Overall, our study showed that Cav-1 play a key role in the initiation and progression of 
CLL and decrease expression of Cav-1 in Eµ-TCL1 mice leads to delayed CLL 
development by decreasing p-Erk signaling.  
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